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Abstract 
 
This paper articulates a citation-based approach to science policy evaluation and employs that 
approach to investigate the impact of the United States’ 2001 policy regarding the Federal 
funding of human embryonic stem cell (hESC) research.  We evaluate the impact of the policy in 
the level of U.S. hESC research, the U.S. position at the knowledge frontier, and the strategic 
response of U.S. scientists. Consistent with recent research on the science of science and 
innovation policy, we employ a difference-in-differences approach using bibliometric data with 
the aim of analyzing the causal impact of the policy on cumulative research.  Our estimates 
suggest that in the aftermath of the 2001 policy, U.S. production of hESC research lagged 35-40 
percent behind anticipated levels.  However, this relative decline was largely concentrated in the 
years 2001-2003 and ameliorated over time.  The rebound in U.S. hESC research was driven by 
contributions by researchers at elite U.S. institutions and U.S. researchers who collaborated with 
international partners.  The results suggest that scientists respond strategically to research 
funding restrictions, and that modest science policy shifts can have a significant influence on the 
within-country composition of research and the pattern of global research collaboration.  
 
Key Words: stem cells, science of science and innovation policy, scientific productivity, R&D 
management, innovation  
 
 
 
 I.  Introduction 
 This paper evaluates whether conditions placed on U.S. Federal funding of human embryonic 
stem cell (hESC) research, as reflected in the August 2001 policy decision of the Bush 
Administration, influenced the level of U.S. hESC scientific activity and the U.S. position at the 
knowledge frontier.  We assess the strategic response of U.S. scientists to this policy intervention, 
specifically examining changes in levels of U.S. research as well as patterns of international 
collaboration and research output by high and low status universities.   
 Taking advantage of recent advances in the use of difference-in-differences methods for 
science policy evaluation, our analysis employs a citation-based approach to establish the causal 
impact of the 2001 hESC policy decision.  Our paper thus makes three contributions.  First, we 
provide direct evidence regarding a key policy question – what was the impact of the 2001 stem cell 
policy decision on the evolution of hESC research in the United States and abroad?  Second, we 
address a more general question of both theoretical and policy interest – how does the targeted 
funding of research influence the direction and evolution of scientific research?  Third, our analysis 
offers a primer regarding the opportunities and challenges associated with a citation-based 
difference-in-differences approach to science policy analysis.  
 Our analysis is motivated by a central question in science policy:  How do conditions on 
scientific funding matter for scientific progress?  On the one hand, a long tradition in science policy 
emphasizes that the evolution of particular research fields or disciplines is guided by the internal 
logic of cumulative discovery and the social structure and norms of scientific communities (Kuhn, 
1962; Merton, 1973; David and Dasgupta, 1994).  At the same time, funders – from governments to 
foundations to corporations – have long attempted to shape the direction of scientific progress by 
conditioning funding on particular research approaches or directions (Dasgutpa and David, 1994; 
Fuchs, 2009, 2010; and see Gans and Murray 2011 for a recent review).  While the aggregate long-
term level of funding for a broad field of course matters (Stephan, 1996; Adams and Griliches, 1996), 
there is much less evidence as to the impact of specific conditions attached to funding on the 
evolution of a scientific field.  Whereas many limitations on scientific funding are developed in 
conjunction with the scientific community (e.g., rules regarding informed consent), other policies are 
imposed on the scientific community based on the politics or preferences of funders.  In this latter 
case, the intended impact of targeted funding may be mitigated to a significant extent through 
strategic behavior on the part of scientists (Aghion, Dewatripont, and Stein, 2008; Murray, 2010; 
Gans and Murray, 2011).  The possibility of strategic behavior undermining the intent of targeted 
funding (or restrictions on funding) is likely to be most salient in settings where the focal scientific 
agenda is considered to be “hot” by the scientific community, when alternative sources of funding 
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may be available, and when scientists largely disagree with the rationale for the funding policy.  The 
key objective of this paper is to evaluate the impact of science policy funding conditions in precisely 
such a circumstance. 
 We specifically examine the impact of the 2001 Bush Administration hESC policy on 
cumulative lines of research that built on the hESC research breakthroughs taking place from 1998 
through 2001.  This is not the first project to examine the impact of hESC policy (see Owen-Smith 
and McCormick, 2006; Levine, 2005, among others).  However, our approach is distinct from prior 
work in developing a citation-based science policy evaluation approach that identifies the precise 
causal linkage between the U.S. policy and the evolution of subsequent scientific research.  Our 
approach builds on citation-based evaluative tools for the “Science of Science and Innovation Policy” 
(Murray and Stern, 2007; Furman and Stern 2010; Murray et al., 2011).   
 Our citation-based approach combines three distinct elements.  First, rather than using the 
count of publications to trace out activities in hESC research in general, we develop a dataset of core 
hESC publications based on a report produced by the National Institutes of Health (2001) and then 
trace out the entire set of forward citations to these articles.  Second, we develop a comparison group 
of papers that were unaffected by the hESC policy in order to construct a well-defined group of 
control articles, allowing us to observe how citations to a similar population of scientific papers 
evolved over time.  Such observations allow us to develop a counterfactual estimate of how the 
citations to the hESC articles would have evolved absent the policy intervention.  While we 
experiment with several control groups, we focus primarily on a group of seminal research papers in 
the area of RNA interference (RNAi), a contemporaneous life sciences breakthrough not directly 
affected by the hESC intervention.1  By comparing the evolution of hESC citations to those from a 
control group, we are able to account for factors such as the globalization of science over time or 
even more specific confounding factors, such as the events of September 11, 2001.  Finally, to 
analyze these data, we apply difference-in-differences econometric techniques to evaluate how the 
pattern of citations to the hESC articles changed in response to the 2001 policy intervention.  
Importantly, we do not simply analyze how the policy impacted the level of hESC research, but focus 
on how the policy changed the geographic distribution of follow-on research, focusing specifically on 
the U.S. relative to other countries.  Additionally, we consider more fine-grained shifts, such as the 
impact of the policy on researchers in different types of institutions (e.g., high-status versus low-
status) or in different types of collaborations (e.g., domestic versus international). 
                                                 
1  The discovery of RNAi was recognized with the award of the 2006 Nobel Prize in Medicine/Physiology to Andrew Fire 
and Craig Mello. 
  3
 Our analysis establishes a number of core findings.  First, our results suggest that U.S.-based 
hESC research experienced a significant decline relative to such research outside the United States in 
the years immediately following the policy’s announcement.  This is consistent with prior work, 
including Owen-Smith and McCormick (2006) and Levine (2008).  However, our research also 
documents a recovery for US-based hESC research after the initial decline in 2001-2003; 
specifically, the relative output of U.S.-based hESC research recovers between 2004 and 2007.  We 
investigate the channels through which this recovery was achieved.  We find that the policy hESC 
output does not affect researchers at elite U.S. universities in the same way as non-elite universities.  
Specifically, we find that hESC researchers at these institutions nearly completely recover from the 
policy shock to hESC output.  In addition, we find that collaborations between U.S. authors and 
researchers outside the United States were impacted to a lesser extent than those papers that did not 
involve cross-national collaborations.  In conjunction with our qualitative research based on 
discussions with hESC researchers (Furman and Murray, 2008), we interpret these results as 
implying (a) that researchers at elite U.S. institutions responded to the policy by developing alternate 
funding mechanisms to support hESC research and (b) that an alternative, and potentially 
complementary, method to continue contributing to hESC research involved collaboration with 
researchers in less restrictive policy environments. 
 The findings in this paper suggest that the scientific community responds strategically to the 
institutional and policy conditions affecting science (Jaffe, 2006; Murray, 2010).  In addition, the 
paper contributes to emerging research on the science of science policy using policy-analytic tools to 
identify the impact of an unanticipated policy on the productivity and organization of science 
(Marburger, 2005; Lane, 2009; Lane and Bertuzzi, 2011).  Finally, our results highlight the 
sensitivity of scientific output to policies which condition research funding in ways that are opposed 
by the scientific community (Gans and Murray, 2011). 
 The remainder of the paper is organized as follows:  In Section II, we outline the citation-
based difference-in-differences approach and compare it to more traditional approaches which focus 
on tracking research activity over time.  Section III introduces the scientific and policy history of 
human embryonic stem cell research and motivates our specific research questions.  Section IV 
describes the application of the citation-based methodology to the hESC data, and Section V presents 
our main empirical results.  A concluding section considers the implications of our findings for 
science policy research. 
 
II. The Citation-based Approach to Science Policy Evaluation 
II.1. Conceptual foundations of citation-based science policy evaluation 
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The citation-based approach to policy evaluation focuses on assessing the impact of critical 
interventions on the process of step-by-step scientific discovery.   Our approach builds on a long 
tradition of the use of bibliometrics in science policy dating back at least to the work of physicist and 
historian of science Derek de Solla Price (1963, 1965).  Traditionally, bibliometric analysis has 
tended to focus on how different policies shape the overall scientific landscape or channel research 
efforts into one domain over another.  In practice, this type of exercise has been done by counting 
publications (or patents) associated with particular keywords, topics, journals, institutions, or 
countries.  This approach has been used to assess a wide variety of policy questions, including the 
role of national institutions on scientific productivity (de Solla Price, 1967), the impact of 
organizational structures and incentives on scientist activity (Levin and Stephan, 1991), or the 
interrelationships among patenting and publication by academic scientists (Azoulay, et al., 2007; 
Ding, Murray and Stuart, 2006).   
Our approach builds on this earlier work but leverages the means by which scientists 
document their processes of step-by-step cumulative scientific discovery and acknowledge the work 
of those upon whom they build.  Specifically, scientific citation and scientific priority are 
fundamental norms of open science (Garfield, 1955; de Solla Price, 1962; Merton, 1973) that we can 
use to track the rate and direction of particular scientific research lines.  While citations are a highly 
imperfect (and noisy) tool for tracking the evolution of particular research lines, the act of 
referencing prior work is both a pervasive scientific norm (with potential professional consequences 
if not followed) that delimits the contribution of any particular follow-on paper.  In other words, 
given the norms and practices of a particular scientific area, scientists have incentives to cite the 
direct work that their discoveries build upon but have few incentives to engage in “gratuitous” 
citation beyond the norms expected by the scientific community.  Not simply a measurement tool, the 
use of a citation-based approach allows us to document process of step-by-step cumulative scientific 
discovery that has been at the heart of modern treatments of scientific and technical progress in 
economics and the history of science (among others, Romer, 1990; Scotchmer, 1991; Aghion and 
Howitt, 1992; Mokyr, 2002; Aghion, Dewatripont and Stein, 2008; Murray, et al., 2011).  While 
citations may sometimes indicate that the prior research is directly being built upon, and in other 
cases serve to highlight the broad outlines of a field, our approach exploits both types of references to 
capture how research conducted prior to a policy intervention informs and shapes research activity 
after the policy intervention.  Our objective is to leverage citation data in order to be able to infer the 
impact of particular policies – such as the 2001 stem cell decision – on the structure and composition 
of follow-on scientific research citations. 
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To identify the causal impact of particular policies on the level and structure of follow-on 
research as measured through citations, we must not simply measure the change in the level of 
citations over time (e.g., before versus after the policy) but must also address what we would have 
anticipated the citation level and structure to be at any point in time in the absence of the policy shift 
we seek to evaluate.  Thus, the second notable difference between this approach and typical 
bibliometric approaches is that we employ citation analysis with the aim of identifying the precise 
causal influence of science policy on cumulative research lines.   Here we draw on advances in the 
program evaluation literature (Angrist and Krueger, 2001; Imbens and Wooldridge, 2009) where the 
aim is to draw causal inference about the impact of specific programs or policy environments by 
looking at exogenous shocks to those programs for a particular population while also tracking the 
behavior of a control group of individuals who would be expected to follow a similar evolution but 
are unaffected by the program change.  In other words, the core idea behind our citation-based 
approach is to evaluate how the evolution of particular research lines changes with changes in the 
institutional or policy environment. To do so, we will take advantage of how the level and structure 
of citations to a group of core articles related to the research line change before and after the policy 
shift, and we will compare that change to the group of citations to those of control articles that are 
expected to have a similar evolution over time but are unaffected by the focal policy shift.  The 
remainder of this section outlines this approach in detail. 
II.2. Key stages in the application of citation-based evaluation 
It is useful to begin our analysis by considering how we would evaluate science policy 
changes in an ideal experimental setting.  In such a setting, a researcher would use citation patterns to 
identify the causal impact of science policy on scientific progress by assigning knowledge to multiple 
distinctive policy environments and then compare citation patterns under each policy regime.  Almost 
by construction, however, the ability to conduct classical experiments interrogating the process of 
scientific discovery is extremely limited given the uniqueness of different scientific trajectories.  
Absent such controls, assessing the causal influence of policy environments on scientific progress is 
beset by a fundamental inference problem.  Specifically, it is difficult to isolate the impact of a policy 
(or program) from the (often highly distinctive) characteristics of knowledge that is impacted by the 
policy.  For example, the observation that researchers who receive more long-term unrestricted 
funding undertake high levels of research or more risky research is hard to interpret in a causal sense.  
On the one hand it could imply that funding conditions cause distinctive research trajectories (a 
treatment effect).  On the other, this empirical finding might simply reflect the fact that researchers 
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attracted to unrestricted funds tend to pursue more risky projects (a selection effect) (Azoulay, Graff-
Zivin and Manso, 2011).   
Our citation-based approach combines four interrelated elements in order to overcome this 
fundamental inference problem.  First, it requires that a policy intervention (or shock) has the 
potential to affect the future cumulative trajectory of knowledge in specific and well-defined research 
areas.  For example, the retraction of research papers constitutes an intervention (at the journal level 
not the policy level) that is intended to influence a specific research trajectory (i.e., it aims to inhibit 
knowledge accumulation based on research acknowledge to be false) (Furman, Jensen, and Murray, 
2012).  A shock that is ideal from a research standpoint should have a number of characteristics.  In 
order to be worthy of research attention, a shock should either shed light on an important theoretical 
issue or have a potentially important impact on cumulative research.  Another critical element in the 
effective application of the citation-based approach is that the policy shock be exogenous, i.e., 
unanticipated by the research community it affects:  By comparing the patterns of knowledge 
accumulation before and after an exogenous policy intervention, investigators can more plausibly 
measure the causal impact of the intervention on scientific progress.  If the intervention were 
anticipated by the research community, then it would be impossible to disentangle with certainty 
whether research behaviors were changing because of the policy or whether changing research 
behaviors augur the policy’s arrival.  It would be ideal if the timing of a shock were unambiguous in 
its onset, as this would enable science policy evaluation to clearly note the pre- and post-shock 
periods and, thus, compare research outcomes before and after the shock takes effect.  The ideal 
shock would have an impact that is extremely precise and can be easily observed in follow-on 
research.  If either the timing of the shock or the research community affected by the shock is 
imprecise, the interpretation of observed results will be murky. For example, if a shock were to apply 
to a range of research areas rather than a single area, it would be difficult to definitively track the 
impact of the shock on follow-on research.  Finally, for identification purposes, it would also be 
helpful if the shock were to affect different “units” of knowledge at different times.  This is not 
absolutely necessary, but can be helpful, as this would enable the econometric analysis to separately 
identify the impact of the shock from the impact of the time period in which it occurred.  For 
example, if a policy is implemented during a particular presidential administration, it may be difficult 
to disentangle whether the policy intervention or other factors associated with the presidential 
administration led to the observed outcomes. 
In addition to requiring a shock of the type described above, the second element of the 
citation-based approach involves pairing the treated research area (i.e., the research area hypothesized 
to be influenced by the policy shift) with a similar research area that is not affected by the policy 
  7
intervention and whose pattern of knowledge accumulation can generate a counterfactual estimate of 
the way in which research would have progressed in the absence of the policy intervention.  In order 
for the control group to generate a counterfactual estimate of the pattern of scientific progress that 
would have occurred had the policy intervention not occurred a number of criteria must be satisfied:  
(1) the control group should not be affected by policy shock; (2) it must have features similar to that 
of treated group prior to shock; and (3) post-shock patterns must be expected to reflect patterns that 
would have occurred in treatment group in the event that treatment did not occur.   In other words, a 
control group is sought that is similar on observable characteristics but is thought not to be impacted 
by the policy intervention (treatment).  The appropriateness of the control group can be evaluated by 
comparing bibliometric features; however, it is also essential to have a qualitative understanding of 
the control group in order to understand the appropriateness of the match.  It is particularly helpful to 
talk to scientists in the “treated” research community to ascertain appropriate control areas of 
research as well as those in the control community.  The unexpected coupling among research areas 
can be problematic when establishing an appropriate control group.2   
Following the determination of a treatment and control research areas, the third element in 
the analysis follows naturally:  identifying a set of “core” research articles that define a body of 
knowledge (in both the treatment and control groups) in the period prior to the policy intervention.  
For example, to explore knowledge trajectories associated with transgenic mice, we use a 
comprehensive database called Mouse Genetics Informatics to help match specific research mice to 
the publications that disclosed information regarding the development and breeding of particular 
mouse model (Murray et al., 2011).  The treatment group in this project included a set of research 
mice over which intellectual property rights changed during the observation period; the control group 
included a set of mouse models used similarly beforehand that were not affected by the shift in IP 
rights. 
To measure knowledge accumulation along particular research lines, we track citations to the 
set of core research papers and interpret forward citations to these articles as evidence of knowledge 
accumulation along the chosen research line.  We acknowledge that citations are noisy measures; 
however, our interpretation of forward citations in this manner relies on the fact that (a) core 
                                                 
2 In several papers including this one, we consider a particular type of control group that we refer to as “nearest neighbors’ 
(see Furman and Stern, 2011; Furman, Jensen and Murray, 2011).  These papers are the next paper published in the journal 
(in chronological order) that is not affected by the particular treatment (e.g. a paper that is not associated with research 
materials or a paper that is not retracted).  These neighboring papers can, in some designs, provide a useful match because 
they meet similar journal quality standards, are of the same age and are generally in the same broad subject area.  If the 
analysis requires an extremely close match in topic space between the treated and control groups, nearest neighbor articles 
may be a poor match when the sample includes general interest journals, like Science, in which articles in physics may 
occupy space next to articles in very different fields, like biology or social science. 
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published papers are produced at a specific and measurable point in time and (b) the way they are 
used by follow-on researchers can be captured and measured in citations with the norms of citation 
neither explicitly changing over time, nor being shifted by the policy.3  Here, too, a detailed 
understanding of the phenomenon, supported by qualitative research, can be extremely helpful.  To 
date, we have found a high fidelity match between core papers and follow-on knowledge 
accumulation in instances where important research materials are developed and disclosed in the core 
papers.  For example, to trace the way in which knowledge associated with particular life science 
research materials accumulates, we (a) match individual research materials to the scientific 
publications that first identify and describe the characteristics of those materials and (b) track forward 
citations to the those reference articles (Furman and Stern, 2011).  By identifying research areas 
where the cumulative follow-on research trajectory builds on key knowledge disclosed in core 
publications, and by closely tracing out the citation relationships between the follow-on research and 
the core publications, we are able to leverage the widespread availability of citation data to evaluate 
the impact of science policy decisions. 
With an exogenous policy intervention identified, mapped to both a treatment and control set 
of research areas and linked to a set of original reference articles and forward citations (reflecting 
knowledge accumulation along their research trajectories), causal analysis can proceed.  This is 
typically accomplished using econometric difference-in-differences techniques (although insights can 
also often be gained from graphical approaches).  In this framework, the annual count of forward 
citations to each “core” research article (treated and controls) is estimated, subject to a variety of 
year, article age, and article fixed effects.  In order to ensure that these are separately identified, it is 
necessary to have variation in article cohort age, as year and age effects will not be separately 
identified if all articles are published in the same year.  The inability to isolate these effects on 
follow-on citations will reduce the ability to identify the main effect of interest.  It is also ideal, 
though not always possible, if the policy intervention were implemented at different times for 
different articles in the affected research line.  This is helpful for identifying the impact of the 
intervention separately from the impact of factors associated with particular points in time, 
represented econometrically by calendar year fixed effects.  For example, the impact of retraction on 
follow-on research can be identified separately from calendar year fixed effects, as various articles 
                                                 
3 We recognize that bibliometric analysis provides only a noisy indicator of scientific progress (see, e.g., Garfield, 1979; 
Lindsey, 1989; and Schubert and Braun, 1993).  For example, for a number of reasons, small differences in the citation 
rate of a single paper (particularly early in its publication history) are of limited value in distinguishing the importance of 
research or its use by the research community.  The citation-based approach to science policy evaluation attempts to 
minimize the impact of these limitations by drawing comparisons among large samples of publications, comparing across 
control samples, and assessing the impact of policy changes by drawing comparisons within articles across time.  
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are retracted in different calendar years.  For policies implemented at a specific point in time, 
however, this identification strategy faces a more severe challenge.    
Citation-based science policy evaluation involves the estimation of difference-in-differences 
models, most often using a count with fixed effects (or conditional fixed effects) for each article, 
which adjust for the fact that different articles have different propensities to generate follow-on 
research.4 The models are often estimated using a negative binomial model because annual citation 
data is skewed to the right and over-dispersed relative to Poisson.  In addition, the rate of citation to a 
given piece of research will vary with the calendar year and with the time elapsed since initial 
publication.  A key variable in the analysis is the “1/0” policy “shock” variable which effectively 
switches the policy on and off in any given calendar year.  In order to interpret a significant result for 
this variable as a statement that the policy intervention caused changes in the patterns of follow-on 
research subsequent to the policy intervention, it is important to reiterate that (a) the changes 
observed following the policy shift did not begin to occur prior to the intervention and (b) the 
research trajectory considered to be affected by the policy shift (the treatment group) can be usefully 
compared to a similar research area that is not affected by the policy intervention. This will enable 
the researcher to identify the “counterfactual,” i.e., the estimate of how the treated research line 
would have developed had the policy intervention not occurred (Imbens and Wooldridge, 2009). 
II.3. Citation-based Science Policy Evaluation vs. other approaches  
The citation-based approach to science policy evaluation will be possible when each of the 
elements articulated above is present.  This approach offers some advantages (and disadvantages) 
relative to publication-based (or keyword) approaches more typically used when asking whether/how 
a policy change (or a change in the institutional environment) impacts the evolution of a stream of 
cumulative research.  It is therefore critical for researchers to determine the most appropriate 
application of each method.   
The approach can be particularly insightful when there is a tight citation-based linkage 
between specific reference articles and follow-on research.  We believe that these linkages are 
relatively strong as shown in our earlier work on access to biological materials (Furman and Stern, 
2011) and research mice (Murray, et al., 2011).  With regards to our analysis of the stem cell policy, 
we make the claim that at least with respect to the core research produced prior to the policy shock, 
any follow-on research article in this area would, almost by definition, cite at least one (or more) of 
                                                 
4 When using a conditional fixed effects estimator, one citation year and one age fixed effect are not separately identified 
(Hall et al., 2007).  As long as the main effect of interest is separable from these effects, a specification can be designed 
to overcome this identification issue.  
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the reference research articles that were published prior to the policy shock.  Indeed, the strong 
materiality of the hESC field is at once the source of the controversy and an indicator of its suitability 
for application to the stem cell setting.  Of course, even in cases with a weaker link to forward 
citations, our approach is salient to the extent that both treatment and control groups operate under 
similar institutional norms for citations.  For example, in our analysis of the impact of retractions on 
knowledge accumulation, both the retracted and non-retracted research are likely to be subject to 
similar (albeit less powerful) citation norms.  
Our methods will be less powerful (and could even be biased) if there is a change to the 
linkage between follow-on research and a core set of research articles.  For example, if the policies of 
interest actually changed the nature of what was cited (for the reference articles but not for the 
controls), it is possible that one could misinterpret a change in citation behavior as a substantive shift 
in research output rather than simply a shift in citation practices.  To give one example, one must be 
careful in evaluating the role of different information technology tools on scholarly publication, as 
these tools are not simply changing the availability of prior research but also the practices and norms 
of citation behavior itself.   Likewise, if one were to believe that in the area of hESC research, 
citation practices were strategically changed in the post-policy period to avoid the attention of 
funders (rather than lower citations being a reflection of lower knowledge accumulation) then the use 
of citation-based approaches would be less applicable. 
A number of additional cautions should be issued in applying the citations-based approach.  
While the identification of policy shocks and control groups is straightforward in principle, they are 
in practice often quite difficult.  Certainly, the citation-based approach is less salient for more general 
policies that were not designed to influence a particular research line, but rather shape overall 
knowledge production or knowledge production.  In this setting, the policy would not likely influence 
specific research lines over others, thus rendering a publication-based approach more suitable.  In 
addition, if a policy shock is likely to move researchers’ preferences entirely out of a particular 
research line and into a different (related or unrelated) area, then the publication-based approach 
would be more suitable.  Moreover, as noted above, researchers must carefully establish that a policy 
shock is truly unanticipated in order for its impact on research trajectories to be estimated.  If the 
shock were anticipated by the research community or were induced by changes in the nature of 
scientific progress, then we could not know for certain whether the policy shift caused the subsequent 
change in knowledge accumulation, whether the post-intervention patterns simultaneously influenced 
and were influenced by the policy shift, or whether the post-intervention patterns preceded the policy 
and, thus, any statistical findings attributing post-intervention patterns of knowledge accumulation to 
the intervention would be specious.  Thus, identifying appropriate science policy interventions can be 
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challenging.  Finally, beyond whether a policy is exogenous, and perhaps most salient for our 
analysis of the hESC policy, it is critical to examine the likely ways in which a particular policy will 
change researchers’ incentives and interests in specific research lines over others.  Absent such an 
understanding, an interpretation of the impact of the policy is extremely challenging.   
 
III. Human Embryonic Stem Cells: Science, Policy & Evaluative Approach  
 We now turn to the specific setting in which we implement our citation-based approach.  We 
first examine the specific nature of the U.S. stem cell policy intervention and its likely impact on the 
willingness of researchers to pursue research building on the hESC breakthroughs that arose in the 
late 1990s.  We pay particular attention to whether or not the policy setting is appropriate to our 
citation-based evaluative approach, particularly highlighting the unexpected nature of the policy 
change, its influence on follow-on research that builds on the initial hESC discoveries and the 
opportunities for follow-on researchers to seek resources from sources beyond the U.S. Federal 
government. 
III.1. hESC Scientific Breakthrough 
 
 In 1998, James Thomson from the University of Wisconsin and his colleagues published an 
unexpected scientific breakthrough in leading journal Science – the first isolation of human 
embryonic stem cells.5,6 Thomson’s publication came 17 years after Evans, Kaufman and Martin 
reported the first isolation of mouse embryonic stem cells (Evans and Kaufman, 1981; Martin, 1981).  
Although Thomson’s lab at Wisconsin had been able to isolate monkey embryonic stem cells two 
years earlier in 1996, their work with human cells came as a surprise to many scientists and scientific 
observers.  Unlike some other advances, the scientific importance of hESCs was recognized 
immediately:  hESCs were acknowledged both as a critical new research tool for basic research in 
embryology and as a gateway for applied research that could lead to novel therapies.  This dual 
contribution in basic and applied research positioned the research squarely in Pasteur’s Quadrant 
                                                 
5  Thomson, through the Wisconsin Alumni Research Fund (WARF) also patented his discovery in the U.S. although 
patents were not granted elsewhere.  As a consequence, one important difference between the policy environments in the 
U.S. and foreign countries is the intellectual property regime.  As this feature of the U.S. environment for hESC research 
does not change contemporaneously with the policy shock, we do not expect that it would confound our analysis or 
results. 
6  This breakthrough built on a century of research in biology that originated with the observation in the 19th century that 
certain cells could produce other cells, most notably blood cells.  Interest in this line of research accelerated in the late 
1960s and 1970s with the development animal based research on in-vitro fertilization techniques, which were propelled 
by practical considerations regarding fertility, embryology and development.  In the 1980s, some physicians and 
scientists began to extend successes with in-vitro fertilization techniques to humans, while others worked with animal-
based embryonic and adult stem cells.    
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(Stokes, 1997).  Indeed, Science hailed the work as a “Breakthrough of the Year” in January 1999.  
The intense interest in stem cells was (and remains) grounded in the fact that “a stem cell is a special 
kind of cell that has a unique capacity to renew itself and to give rise to specialized cell types.  
Although most cells of the body, such as heart cells or skin cells, are committed to conducting a 
specific function, a stem cell is uncommitted and remains uncommitted, until it receives a signal to 
develop into a specialized cell.  Their proliferative capacity combined with the ability to become 
specialized makes stem cells unique [emphasis added]” (NIH, 2001, ES-1).  Thus, both the scientific 
and medical promise of stem cell research derives from its potential to develop multiple types of 
cells.   
 The potential of human ESCs as a basis for human therapeutics was also the basis of their 
controversy – they were derived from human cells and, unlike other forms of “adult” stem cells, they 
were derived from embryos.  The distinction between adult stem cells and embryonic stem cells is 
central to the hESC debate (and our some aspects of our approach to evaluation): “An adult stem cell 
is an undifferentiated cell that is found in a differentiated (specialized) tissue in the adult, such as 
blood.  It can yield the specialized cell types of the tissue from which it originated [and…] can renew 
itself” (NIH, 2001, ES-1).  In other words, while it can be transformed into a number of differentiated 
cell-types, it cannot give rise to all types of specialized cells. By contrast, embryonic stem cells are 
derived from embryos and are pluripotent; unlike adult stem cells, they can develop into any of the 
over 200 cell types in the body.  Therefore, as of the late 1990s and 2000s, leading scientists regarded 
embryonic stem cells as holding more promise as research tools and as medical therapies because of 
their greater ability to differentiate leading to considerable interest in and attention on embryonic 
stem cell research in general.  What made the Thomson breakthrough particularly significant and 
controversial was its heralding of the ability to isolate and manipulate embryonic stem cells from 
humans rather than from other sources, such as mice or monkeys, a step of great significance from a 
medical perspective and a step that many regarded as likely to form the basis of important follow-on 
research building on Thomson’s results and materials.  
 Thomson was not entirely alone in focusing attention on hESCs:  During the late 1990s, 
hESC research was taking place in a very small number of international laboratories.  Aside from 
Thomson’s laboratory in Wisconsin, leading researchers included a small group in Israel, Australia 
and the United Kingdom.   Perhaps not surprisingly, these groups are not entirely independent of one 
another.  Thomson had a long running collaboration with Israeli scientist Joseph Itzkowitz-Eldor, 
who, in turn, co-authored a series of hESC papers with Nissim Benvenisty. In Australia, Pera and 
Trounson worked closely and collaborated with Bongso in Singapore.  Indeed, the U.S., Israel, 
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England, and Canada are the only countries associated with the reprint authors of the “core” hESC 
research articles listed as seminal in hESC prior to 2001 (see Table 1, Panel C). 
 Whether building on the research of Thomson or other seminal papers in the field by 
international scholars, U.S. researchers had to determine whether the policy context would allow 
them to pursue hESC research and provide funding for their ongoing research. 
 
III.2. U.S. Stem Cell Policy Context: 1970 - 2001 
 In the decade prior to Thomson’s work, there had been considerable debate over the 
appropriate levels of support for research on human embryos, which were necessary for the isolation 
of human embryonic stem cells with methods developed by Thomson and others.  Beginning in 1973, 
U.S. government policies prohibited federal funding from supporting research on fetuses, embryos, 
and tissues associated with either.  These restrictions did not, however, impose bans on private sector 
or privately funded research (Wertz, 2002).7  What followed was a period with significant policy 
uncertainty.  In 1993, the Democratic-majority Congress passed the National Institutes of Health 
Revitalization Act, which would have enabled the NIH to distribute funds for research on human 
embryos.  In interpreting the Act, the Clinton Administration offered partial support for research on 
human embryos, but prohibited the NIH from funding experiments that would create embryos 
exclusively for research purposes.  In 1995, however, the Republican-majority Congress passed the 
more restrictive Dickey-Wicker Amendment, which expressly prohibited federal funding for research 
in which human embryos were either created or destroyed.  This limitation essentially precluded 
federal support for research on in vitro fertilization, which generally creates more embryos than are 
actually used in fertility treatment, and hence implicitly for hESC research, although this was 
considered a legal gray area. It was in this context that Thomson himself had received and used 
corporate funding from biotechnology company Geron to support his research on hESC isolation. 
 In the two years following Thomson’s breakthrough (the final years of the Clinton 
Administration), the policy environment became significantly more inclined towards federal support 
for human embryonic stem cell research.  And, in August 2000, only a few months before the Bush 
vs. Gore presidential election, the NIH published guidelines enabling federal funding for research 
using existing cell lines, and it solicited proposals for future research, which it intended to adjudicate 
                                                 
7  In the late 1980s, both the National Institutes of Health (NIH) and Congress became more sympathetic to the prospect of 
using government funding for research on human embryos.  Although the NIH’s Human Fetal Tissue Transplantation 
Research Panel voted overwhelmingly in favor of support for funding research involving fetal tissue and human embryos, 
DHHS Secretary Louis Sullivan rejected the Panel’s recommendation and extended the ban on such funding (Wertz, 
2002). 
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in March 2001.8  Although the prior few years had involve a substantial gathering of momentum for 
supporting hESC research, the Presidential election led scientists to be uncertain about the policy 
context they would find in 2001.  There were sharp contrasts in the policy proposals on the table from 
the Democratic presidential candidate Al Gore and the Republican candidate.  A closely fought 
election and contentious outcome, which ultimately resulted in President George Bush as the 
Republican President continued to fuel the uncertainty.  Thus, the United States began 2001 amidst a 
contentious public debate and an evolving, uncertain policy environment. 
 The scientific community actively touted the prospective value of hESC research and 
remained hopeful about the prospects for large-scale funding.  President Bush therefore initiated an 
official review of policy options with respect to human embryonic stem cell research.  His 
administration placed, however, a hold on all funding of hESC proposals solicited by the NIH.  In 
February 2001, as part of the administration’s review process, Tommy Thompson, the Secretary of 
Health and Human Services, requested “that the National Institutes of Health prepare a summary 
report on the state of the science on stem cells … [which] provides the current information about the 
biology of stem cells derived from all sources— embryo, fetal tissue, and adult” (NIH, 2001, p. i).  
The NIH issued its report, “Stem Cells:  Scientific Progress and Future Research Directions,” later 
that year, in June 2001 (as we outline in Section IV we will use the research articles described in this 
document as the source of the core articles describing breakthrough knowledge of hESC in the period 
prior to the policy intervention). 
 In August 2001, President Bush introduced his administration’s policy.  It was met with 
considerable surprise in the U.S. media and by many scientists.9  The announced policy involved 
compromise between opposing viewpoints.  Specifically, the announced policy neither involved a 
full ban on hESC research, nor provided unrestricted funding for hESC research.  Instead, the policy 
offered federal support for hESC research, subject to conditions on research materials.  The policy 
included three features that are notable for our current project:  The policy (1) enabled federal 
funding for research on the set of human embryonic cell lines that were already existed at the time of 
the policy (including cell lines that were reported in the breakthrough work of Thomson and others 
                                                 
8  The Clinton Administration’s reversal was based on an opinion provided by Harriett Rabb, then General Counsel at the 
DHHS, to Harold Varmus, then Director of the NIH, in which Rabb concluded that funding research using hESCs that 
were not derived with federal funds would not violate the Dickey Amendment because hESCs do not meet the definition 
of embryos (Rabb, 1999; NIH, 1999).   
9 In addition to being a genuine surprise, the Bush policy was met with negative reactions from both the right and left of the 
political spectrum (Wertz, 2002) and with substantial disappointment within the scientific community (Clark, 2001; 
McGinley and Regalado, 2002).  Among other arguments, opponents of hESC research were dismayed that research 
associated with the destruction of embryos was permitted under the Bush Administration policy, while proponents of 
hESC research argued that the limitations on federal funding would inhibit scientific advances and retard medical 
improvements (Wertz, 2002).   
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outside the U.S., such as those developed by Trounson in Australia); (2) prohibited federal funding 
for the development of and research on new human embryonic cell lines; and (3) placed no 
restrictions on the use of private, state, or local funds for hESC research purposes.   Although the 
policy (a) offered the first unimpeded path to Federal funding of research involving human 
embryonic stem cells (the Clinton Administration initiated funding requests but did not make grants) 
and (b) did not place restrictions on private or state-level hESC research funding, the policy 
constrained scientists with respect to the research materials they could use.  Thus, the policy involved 
targeted research funding, which constrained the autonomy of researchers to choose materials in 
projects involving Federal grants.  
 Based on these details, the U.S. hESC policy intervention seems appropriate for evaluation in 
a citation-based casual framework.  First, the policy applies to a specific research area in a way that 
may alter follow-on research that builds upon a core set of published articles – i.e., the policy directly 
bears upon follow-on work in hESC research, but does not directly influence work on other areas of 
research in cell biology.  As well, the intervention was expected to be of considerable importance for 
hESC research, an area expected to have promising implications for medical science.  Also of 
importance for our research design, the policy shock appears to have been exogenous.  There is 
ample evidence of the significant uncertainty in the policy environment surrounding hESC research 
in the period prior to the policy decision – exacerbated by the uncertainty of the Presidential elections 
– and the decision itself was also unexpectedly subtle and nuanced.  Though the policy intervention 
appears suitable for analysis in our framework, it could be more ideal.  The policy’s nuance leaves 
room for interpretation of whether to consider the shock as one that provides targeted funding for 
some research areas or imposes funding restrictions relative to the rest of the world.   The timing of 
the shock involves a period of uncertainty (in 2000, which we would expect to have an impact on 
research output in 2001) and the August 2001 policy intervention itself, which we expect to have an 
impact on research in the years thereafter. 
 
III.3. Post-2001 Research Context, U.S. and Abroad 
 From the perspective of researchers with an interest in pursuing hESC research within the 
United States, a complex variety of options were now available.  Researchers interested in pursuing 
hESC research using approved lines could apply for NIH and other government support to do so.  
And resources were now available:  Of the approximately $550 million devoted to stem cell research 
in 2005 by the U.S. federal government, about $24 million was devoted to human embryonic stem 
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cell research (Beardsley, 2005).10  Researchers interested in applying for NIH grants for support for 
research using approved hESC lines could do so; however, few of the human embryonic stem cells 
created before August 2001 are valuable for therapeutic purposes, as the majority were contaminated 
by mouse embryonic feeder cultures (Martin et al, 2005). 
 The policy also formally opened an avenue for interested non-federal actors to support hESC 
research efforts (albeit a complex one from the perspective of funding logistics).   Researchers could 
receive private funding for projects using either approved or non-approved hESC lines.  However, 
those researchers with funding for non-approved hESC lines who also received federal support for 
research on approved lines were obligated to establish laboratories that were physically and 
organizationally distinct from one another.  Not extensively documented, private funding was 
available to researchers from both corporate sources as well as from private philanthropic sources.  
For example, Thomson continued to receive funding from the private biotechnology company Geron 
for his hESC research at the University of Wisconsin.  Moreover, soon after the 2001 policy 
announcement, leading institutions such as Harvard University initiated major fund raising efforts 
with private philanthropic donors interested in pursuing the promise of hESC research focus on 
specific medical applications, such as diabetes.  Again, such funding had to be used carefully with 
strict provisions established around the co-mingling of funds in specific projects and in the 
laboratory.  Precise estimates of annual private hESC research funding are difficult to obtain; based 
on high-profile public pledges to major universities and the support of for-profit corporations, such as 
Geron, it appears as if private funding of hESC research approximated that of public research in the 
years following the policy intervention.11   
 In addition to the private sources of funding described above, the policies enacted by the 
Federal government left substantial room for both funding and policy choices at the state level.  Some 
states (e.g. Louisiana, South Dakota, Kansas, and Nebraska) enacted restrictive policies.  At one 
extreme, Louisiana established a complete ban on the use or destruction of embryos for any purpose 
and recognized embryos legally as “juridical persons” (Rewerski, 2007).  In general, however, 
restrictive state bans did not arise in states that were in a strong position to capitalize on Thomson’s 
research and build cumulatively on the hESC agenda.  States with a strong record in the life sciences 
                                                 
10 The NIH reports spending approximately $938 million on overall stem cell research in FY2008, of which $88 million 
was targeted for hESC research (NIH, 2011).  For the sake of relative comparison, the NIH provided $5.5 billion for 
Cancer research, $3.5 billion for Women’s Health, $1.4 billion for Nutritional Health, $400 million for  Depression 
research, $225 for Sleep research, and $80 million each for research on Sickle Cell Disease and Spinal Cord Injury (NIH, 
2011).  
11 For example, a series of institutions, including Cornell University, Harvard University, Sloan-Kettering Memorial Cancer 
Institute, (as well as other universities, such as Johns Hopkins, Stanford, and UCLA) have received pledges from private 
sources greater than $10 million each (Hughes, 2006).  
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were among those states that enacted more permissive policies. And, several state governments 
authorized funding for hESC research or facilities subsequent to the Bush Administration policy 
announcement (California, Connecticut, Illinois, Maryland, Massachusetts, New Jersey, New York, 
Wisconsin (Vestal, 2009)).  State-sponsored funding did not, however, arrive swiftly.  In December 
2005, New Jersey became the first state to administer funds for research projects.  Even as late as 
2007, only a limited fraction of state-approved funding had materialized in the form of research 
grants (Vestal, 2007).12  
 Yet a third source of resources for U.S. researchers was to seek well-funded collaborators in 
countries outside the United States whose policy frameworks and government funding enabled joint 
research on hESC projects using both “mandated” and new human embryonic stem cell lines.  As 
noted above, the international research community in hESC research prior to 2001 was small with 
only a handful of labs having developed and sustained the expertise to isolate and maintain human 
embryonic stem cell lines.   U.S. researchers therefore had a relatively “thin” albeit expanding 
research community from which to draw if they sought to find non-U.S. collaborators.  Of course, 
with global collaboration came the need to navigate an extremely complex international policy 
context, to understand the global community of hESC researchers, and to find a division of labor that 
allowed hESC work to take place outside the U.S. with complementary efforts inside the U.S. labs.   
 In the post-2001 policy period, a number of European countries - including Austria, Ireland, 
and Italy - did not permit scientists to derive stem cell lines, conduct research on existing lines, or 
conduct research involving somatic cell nuclear transfer.  Germany allowed research on existing 
lines, but prohibited nuclear transfer and the derivation of new lines.  Countries with more permissive 
policies, however, included a number of leading research nations: Israel, Singapore, Sweden, and the 
United Kingdom, as well as some of the rapid followers such as China, Japan, and South Korea 
(Walters, 2004). Indeed, nations including the U.K., Israel, and several Asian nations generally 
increased their commitment to hESC research and hoped to gain a comparative advantage in hESC 
research.  However, the level of funding was highly limited compared to the (albeit limited) levels 
available in the U.S.  Although it would be attractive to explore the impact of specific national 
policies on country-specific hESC research output, it does not appear as if the data and phenomenon 
support our ability to do this, as we do not have well-defined policy interventions outside the United 
                                                 
12  The U.S. Administration Stem Cell policy was altered in March 2009 when President Barack Obama issued an executive 
order overturning the ban on the use of federal funding for deriving new human embryonic stem cell lines and conducting 
research lines derived after August 2001.  The NIH authorized approximately $20 million in funding for human 
embryonic stem cell research in 2009 and approved the first set of new hESC lines in December 2009.  Our data do not, 
however, cover this new period of policy, however, as these changes would be too recent to analyze with confidence.  
Since the Obama Administration’s order in 2009, a series of additional political and legal actions have created further 
uncertainty regarding the extent of future hESC funding in the United States. 
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States (a) that involve unanticipated shocks and (b) that affect a sufficiently large segment of 
researchers that would enable us to identify the causal impact of national policies on hESC 
production.  These limitations also inhibit our ability to identify the impact of the U.S. policy shock 
on hESC research output in individual countries other than the United States.  
 Our descriptive statistics will illustrate (see Section V) among citations to the core hESC 
research articles prior to 2002 (i.e. citations to hESC articles in the pre-policy period), the U.K., 
Germany, Australia, Japan and Israel dominate.  In later periods, researchers from China, South 
Korea and Singapore also start to make significant contributes to the area of hESC research, in line 
with both growing investments in science overall but also with their open policies towards hESC 
research.  It is, however, important to note two additional facts about hESC research production and 
policy outside the United States that are particularly critical for our research design:  (1) the 
production of hESC in countries other than the U.S. was not highly concentrated (Levine, 2005) and 
(2) while the policy landscape was dynamic, few countries undertook radical changes in their hESC 
policies contemporaneously with or as a result of the Bush policy and there were no large-scale 
policy shifts synchronized across a number of countries that could be thought to interfere with our 
policy analysis.  
 
III.4. Predictions regarding the impact of the hESC policy intervention  
 We interpret the Bush Administration policy shock as involving two related elements.  First, 
we consider the period of uncertainty around the 2000 Presidential election and the period preceding 
the announcement of the Bush Administration policy as constituting a shock relative to the 
expectations regarding future hESC research funding building during the Clinton Administration.  
We expect that this shock would have a negative impact on U.S. hESC research relative to other 
countries that did not experience this uncertainty during this particular year.  Second, we consider the 
implementation of the Bush Administration policy beginning in August 2001 as constituting an 
intervention that shifted the attractiveness of hESC research in the United States (in comparison to 
other fields) relative to the rest of the world (i.e., making the prospect of hESC in the U.S. less 
attractive relative to the pre-Bush period, and hence, relatively less attractive to U.S. researchers than 
non-U.S. researchers who did not experience a shock in this particular period).  Although the policy 
ensure that Federal funding would, indeed, by available for hESC research, we expect that the 
targeting of the funding to a restricted set of research materials, would yield a reduced the level of 
participation in human embryonic stem cell research in the United States relative to the rest of the 
world, in which such research fund targeting was not enacted beginning in that period.  
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 Specifically, in the post-August 2001 period, U.S.-based scientists were faced with relatively 
higher difficulty accessing particular hESC materials; thus, we anticipate that scientists faced with 
these constraints would be relatively less likely to participate in hESC research, a prediction in line 
with recent studies of the role of biological resource centers in increasing participation in research 
lines associated with easily accessible materials (Furman and Stern, 2011).13  This prediction is also 
consistent with recent literature emphasizing the importance of research freedom to scientists, and 
with earlier research that emphasizes the importance of field size and legitimacy for continued 
researcher commitment (Garud and Rappa, 1995).   
 While our first prediction is simple in its formulation, recent studies suggest additional 
predictions that would highlight the factors that shape scientists’ responses to the hESC intervention.  
Specifically, qualitative studies have countered the view that scientists are passive recipients of the 
organizational rules, incentives and governance systems imposed by those who fund them, and 
reports have challenged the idea that scientists simply conform to any changes imposed on them.  
Indeed, there is evidence to suggest that the very autonomy and strong normative nature of the 
scientific community allows scientists to engage higher levels of strategic action than previously 
anticipated.  For example, Murray (2010) recounts the response of the “mouse community,” a 
community of scholars that employ mice in research, to Dupont’s exercise of strong patent rights 
over mice bred with a genetic predisposition to cancer.  Qualitative evidence documents mouse 
researchers’ attempts to subvert or ignore the intrusion to their research freedom and suggests that 
those scientists with greater resources take higher levels of strategic action.  In other words, when 
confronted by expanding restrictions on their use of research inputs, scientists construe these actions 
as intrusions on their scientific freedom and take strategic action to respond and resist, with the aim 
of pursuing the research paths that they perceive to be most valuable.   
 Accordingly, we predict that the higher status scientists, who possess greater access to both 
financial capital and social capital, are less likely to be affected by policy targeting.  Instead, over 
time, they would use their resources to buffer themselves from policies that attempt to steer their 
research choices in a direction not of their own choosing.  During the period of our analysis, new 
hESC research lines were perceived by scientists to have greater scientific potential, on average, than 
the lines approved for funding under the Bush Administration.  Thus, we expect that researchers with 
the status or other means to do so would identify ways to continue participating in hESC research 
efforts.  Specifically, we predict that scientists at high status universities and those with international 
                                                 
13 The popular press worried openly about the possible negative impact of the policy on U.S. competitiveness in hESC 
research (Clark, 2001; Anand and Regalado, 2002) and similar concerns were expressed by members of the scientific 
community in leading journals such as Science (Vogel, 2001) and the Nature journals (Smaglik, 2001; Fletcher, 2001).  
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collaborators will find strategies to circumvent the controls on research direction, and thus exhibit 
higher levels of research participation, lowering the impact of funding boundaries on their levels of 
participation in hESC research. 
 Taken together, our predictions suggest that the 2001 hESC policy will have a significant 
impact on U.S. scientists attempting to build upon the important research trajectories established in 
hESC research in the period from 1998 to 2000.  This impact will be one of a significant decline, 
relative to their foreign counterparts and relative to expected trends in the globalization of research 
along high impact research trajectories.  In addition, we predict that there will be a differential impact 
on different groups of U.S scientists, again relative to expected trends.  To evaluate these questions, 
we use the citation-based evaluation approach outlined above.  In the section that follows we describe 
our methods paying particular attention to the development of the core set of (treated) hESC research 
articles and the different groups of control articles.  This is essential because our results are 
predicated not only on capturing differences in research trajectories pre- and post- the policy 
intervention but also on evaluating those differences relative to a well-defined counterfactual. 
 
IV.  hESC policy evaluation:  Design, estimation and data 
IV.1. Research design 
Our methodological approach to evaluating the 2001 hESC policy follows the critical steps 
laid out more generally in Section II.  We take the core set of hESC research articles from 1998-2000 
and use the core set of RNAi research articles during the same period as our primary counterfactual.  
We then implement a difference-in-differences analysis to estimate the impact of the 2001 hESC 
policy intervention on the trajectory of human embryonic stem cell research (i.e. comparing the pre- 
and post- policy citation trends) relative to that of our RNAi controls for U.S. researchers.  The 
citation-based approach we follow here differs from the publication-based and keyword oriented 
approach used in prior policy evaluations of the hESC intervention.  In particular, Owen-Smith and 
co-authors (Owen-Smith and McCormick, 2006; McCormick, et al., 2009; Scott, et al., 2009, 2010, 
2011)) as well as Levine (2005; 2008) and Löser et al. (2009) have explored the flows of scientific 
knowledge in the stem cell arena tracing out the patterns of stem cell research (using keywords) over 
time and across geographies, thus providing important insights into the general patterns of hESC and 
other stem cell research overall.  The methods used in these studies provide key insights into broad 
patterns of hESC research.  In contrast, our citation-based approach focuses very explicitly on what 
happens to follow-on research that builds on the core hESC breakthroughs after the policy shift that 
changed the conditions of and incentives for these trajectories.  There are clearly benefits as well as 
costs to the citation-based methodology in the context of the hESC policy intervention.  Unlike the 
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keyword approach, we cannot capture research that establishes entirely new and novel approaches to 
the production and isolation of hESCs, i.e., to totally new and unconnected research lines.  In other 
words, this approach is very poor at evaluating policy shifts that move research to entirely new fields 
of enquiry or to exploring individual researchers’ choices of disconnected arenas.  In contrast, 
however, we can provide a much more precise estimate of the causal impact of the policy on the 
hESC trajectory overall and more specifically on U.S. researchers in different types of institutions. 
 A core element of our research design is the identification of a plausibly exogenous shock to 
cumulative research in a particular trajectory.  In this case, the shock involves the resolution of the 
2000 U.S. presidential election and the subsequent 2001 announcement of the Bush Administration’s 
hESC funding policy.  Considering this as the policy shock around which we build our analysis 
involves the assumption that the policy intervention constituted an exogenous shock suitable for 
analysis in our framework.  As we describe in Section III.4, we believe that the historical record 
suggests this to be a reasonable assumption.14 
Accordingly, we conceive of the U.S. hESC research landscape as consisting of the pre-
election period, the period between the announcement of 2000 election results (in December 2000), 
and the period following the announcement of the Bush Administration policy (in August 2001), 
during which the policy intervention may influence the rate and nature of cumulative hESC research 
efforts.  Considering that the delay between research project initiation and publication is 
approximately six months to a year, we believe that it makes sense to consider the pre-2001 period as 
the “pre-intervention” period in the analysis, the year 2001 as the year in which the results of the 
election may have an impact on hESC publication, and the years after 2001 as the period in which the 
impact of the announced policy can be ascertained. 
 Having defined a policy intervention that may affect cumulative knowledge, the next step in 
applying our methodological approach involves identifying a clear control group that can help 
provide a counterfactual estimate of the trajectory of follow-on hESC research.  The trajectory of 
research in RNA interference (RNAi) constitutes our primary control group, although we examine 
two additional potential controls in our robustness checks.   
                                                 
14 The hESC research community had reason to expect that the Bush Administration may not be as supportive of hESC 
research as was the Clinton Administration.  This was borne out by the NIH’s ceasing evaluation of previously-submitted 
hESC proposals, which effectively reversed the course followed towards the end of the Clinton Administration, which 
had announced expectations regarding funding hESC work.  The resolution of the uncertainty seemed favorable relative 
to expectation that hESC research may be forbidden by the Bush Administration.  Indeed, the Bush policy mandated the 
first federal funding for hESC research.  However, the condition that only pre-existing cell lines would be eligible for 
federal support was interpreted by many in the scientific community as a restriction on funding for research materials 
relative to their expectations prior to the Bush electoral victory.   
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 RNAi research has several important characteristics that allow it to serve as an appropriate 
control group.  It represents a scientific breakthrough that was (a) pioneered in the United States 
achieved, (b) in essentially the same field and at the same time as hESC research (1998), and (c) 
perceived to be of similar scientific importance in 2001.  Thus, hESC research and RNAi research 
share similarities in that both were life science breakthroughs, pioneered in the U.S. in 1998, and that 
each diffused to the rest of the world at similar rates prior to the 2001 policy intervention.  It is also 
helpful that, unlike some other areas of research, including stem cell research involving adult stem 
cells or animal models, methods in RNAi and hESC are relatively independent.  It is difficult for 
researchers to simultaneously conduct or to substitute between RNAi and hESC research and, 
according to our qualitative evidence, researchers do not use both methods in their laboratories.  
Hence, a policy shock affecting the extent and organization of U.S.-based hESC research is not likely 
to have a direct impact on RNAi research.  Moreover, unlike hESC research, RNAi was not subject 
to any specific policy intervention during the time of our analysis.  Based on similar considerations, 
Levine (2008) also argues for the suitability of RNAi as a comparison field for hESC.   
 The next step in implementing our approach is to link the treated and control groups with a 
set of reference articles that reflect core knowledge in each area.  To do this for hESC research, we 
rely upon a sample of stem cell articles identified by the NIH report, “Stem Cells:  Scientific Progress 
and Future Research Directions.”  This report was published in June 2001 and was developed to be 
an input into the Administration’s policy-making process.  The report was devoted to scientific facts 
relevant to the policy debate, but does not appear to be a political document.15  Importantly for our 
research design, the document identifies 110 articles deemed by the NIH to reflect the seminal 
articles in stem cell research, including papers associated with embryonic and adult stem cells 
derived from both human and animal models.  We consider the 17 hESC articles to be our core 
articles – our primary treatment sample.  (Of these, one article is not referenced in the ISI Web of 
Science data set, so our primary hESC sample involves citations to the 16 remaining articles.)  To 
identify the core research on which the RNAi research trajectory builds, we rely upon the list of 
seminal RNAi articles published by Ambion Inc., a company that manufactures and markets products 
related to RNAi-research.  The list includes 56 articles, of which 52 were published prior to or during 
2001 and 4 of which were published in 2002.16 
                                                 
15 The report notes in its Preface, “NIH recognizes the compelling ethical and legal issues surrounding human pluripotent 
stem cell research. Because extensive discussions regarding these issues have been presented in various forums 
elsewhere, they are not part of this review of the state of the science.  Also, the report does not make recommendations 
pertaining to the policies governing federal funding of such research” (NIH, 2001, p. II).   
16 Our results are not sensitive to including or omitting the four RNAI articles published in 2002. 
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 While considering RNAi core articles as our primary control sample, we do examine two 
alternative control samples, which we include in data comparisons and in robustness checks, although 
we do not consider them to be ideal controls.  These samples include (i) a set of matched articles 
appearing in the same journals at the same time as the hESC treatment articles, which we call 
“nearest neighbor” articles (following Furman and Stern, 2011) and (ii) areas of stem cell research 
that involve either adult stem cells or animal stem cell models (i.e., stem cell research other than 
hESC).  The nearest neighbor sample consists of the three articles that immediately proceed and 
follow each of the root hESC articles in the same year and issue of the journal in which the hESC 
root article was published.  The nearest neighbor articles are, therefore, precisely matched with the 
hESC articles with respect to publication timing and journal.  They may, however, be poorly matched 
with respect to scientific field; this is particularly apt to be the case for articles that appear in general 
interest science journals, such as Science and Nature, in which articles in life sciences may be 
published contiguously with articles in physics or even social sciences.  The nearest neighbor articles 
are also less likely to be matched in scientific importance.  Thus, we do not consider the nearest 
neighbors to be an ideal control sample, as we feel believe that it is more reasonable to rely on 
comparisons to another “hot” area of science like RNAi than to areas of “normal science,” as these 
types of research may be subject to different dynamics (Kuhn, 1962). 
 Stem cell research using adult or animal models (“Other Stem Cell” research) is intuitively 
appealing as a control group as it bears direct similarity to hESC research and because the Bush 
Administration hESC policy did not alter funding for these areas of research.  In addition, 93 seminal 
OSC reference articles are identified by the same NIH Report from which we draw our hESC 
reference articles.  After considerable discussion with scientific expertise, however, we decided 
against using OSCs as our main control group because the extent of research in this area was likely 
affected by the Bush Administration policy in an important, though indirect, way.  When researchers 
interested in pursuing hESC research faced a limited set of funding options and examined alternative 
research paths to pursue, the use of animal ESCs or adult stem cells were natural alternatives.  
Indeed, many laboratories at the time (and today) used a combination of stem cell methods and 
materials.  Consequently, by the 2001 policy intervention would likely involve substitution between 
hESC and OSC research.  As a result, OSC research does not constitute an independent control that 
could establish a clear counterfactual to hESC research, but is more similar to another “quasi-
treatment” group, subject to a different but related treatment.   
 
IV.2. Estimation 
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The final element of our research approach involves econometrically estimating the causal 
impact of the 2001 policy on U.S. hESC research relative to Non-U.S. hESC research.  The intuition 
behind the approach is that draws two simultaneous comparisons.  We (a) compare citations to core 
hESC articles from U.S.-based reprint authors vs. citations from Non-U.S. reprint authors before and 
after the policy intervention and (b) compare these trends to differences in citations to core RNAi 
articles from U.S.-based and Non-U.S.-based reprint authors.  The comparison of U.S. to Non-U.S. 
RNAi citations establishes a baseline relative to which we can then compare trends in U.S. and Non-
U.S. hESC citations.  In principle, this is similar to the descriptive analysis by Levine (2008), which 
compares country-level counts of citations to Thomson et al.’s (1998) seminal hESC paper with those 
to Fire et al.’s seminal RNAi paper, both before and after the policy intervention.  The central 
advantages associated with using econometric analysis, rather than straightforward counts, are that 
the differences-in-differences techniques we employ are able to identify fine-grained trends, 
including year-to-year trends, in relative hESC and RNAI research output and are able to provide 
precise estimates (i.e., percentage increases or decreases) of the causal impact of the hESC policy 
intervention on post-intervention output in the United States. 
Estimating the impact of the policy intervention econometrically is complicated by the fact 
that the analysis requires two different dependent variables, one reflecting citations by U.S.-based 
and another citations by Non-U.S. based reprint authors.  One way to do this would be to run these 
models separately, including the same dependent variables in each model and then comparing the 
coefficients indicating the post-policy impact on each.  A drawback of this approach is that it will, 
necessarily, assume that the set of factors driving U.S. and Non-U.S. citations is different.  This 
makes it difficult to compare coefficients indicating the impact of the policy intervention on citations.  
To overcome this difficulty, we simultaneously estimate the drivers of U.S. and Non-U.S. 
citations in a single equation, using a single dependent variable, ritCITES , with a data structure that 
involves replicating the entire dataset twice by “stacking” the data upon itself.  The top half (top 
stack) of the resulting dataset differs from the bottom half (bottom stack) in one key way.  In the top 
half (stack) of the data, the variable ritCITES reflects citations generated by U.S.-based reprint 
authors (i.e., r USitCITES
 ), while, in the bottom half (stack), it reflects citations by papers whose 
reprint authors are from countries other than the United States (i.e., r NotUSitCITES
 ).  The superscript 
r indexes whether the data are from the “U.S. stack” or the “Non-U.S. stack” of the data.  The 
resulting dataset also includes a stack-specific dummy variable indicating that the top half is the U.S. 
stack and that the bottom stack is the Non-U.S. stack.  With these exceptions, however, the top and 
bottom stacks include exactly the same data.  Organizing the data in this structure enables us to 
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identify the impact of U.S. policy on citations generated by U.S.-based authors relative to the impact 
of these policy periods on citations generated by authors based in other countries, holding all other 
variables constant that simultaneously affect citations in the U.S. and the rest of the world. This 
approach follows that of Furman and Stern (2011) and Murray et al. (2011). 
With this data structure in place, we estimate: 
(1) 0 1
0 1
( ; *2001 *( 2001 )
( * *2001 ) ( * *( 2001 ))
r r r
it it i t t pubyear i it i it
r r
i i it i i it
CITES f HESC HESC t
US HESC US HESC t
     
 
      
   
where the superscript r denotes the region to which the variable pertains (r = either U.S. or Non-U.S., 
depending on the address of the article’s reprint author), i indexes each article and t indexes each 
year, while (i) is a fixed effect for each article, t is a year effect, t-pubyear captures the age of the 
article, and HESC*2001 and HESC*(2002-2007) represent dummy variables equal to one for hESC 
articles in years 2001 and 2002-2007, respectively.17  The coefficients on these variables (1 and 2) 
identify the difference in follow-on research experienced by hESC core articles (both associated with 
U.S. and Non-U.S. reprint authors) relative to the control articles during the 2001 and 2002-2007 
time periods.  The coefficients  and  are the central focus of our analysis.  These indicate the 
marginal impact of the policy intervention on follow-on research in the United States relative to the 
rest of the world and relative to follow-on research in the control group.  In other words, these 
coefficients indicate the additional increment or decrement to citations that hESC root articles receive 
in the U.S. relative to the rest of the world in the year of and the years subsequent to the policy 
intervention. 
The specification includes one key parametric restriction:  We estimate the reference article 
fixed effects (i) to be equal in each stack of the data.  We allow calendar year and article age fixed 
effects to vary by stack, however.  By estimating the stacked regression, rather than estimating the 
drivers of CITES separately for the U.S. and Non-U.S. authors, we are able to interpret  and  as 
indicators of the change in hESC article output in 2001 and the years after the policy shift relative to 
hESC article output in the rest of the world.  
                                                 
17  Several issues, including the incidental parameters problem, arise in incorporating multiple fixed effect vectors into a 
negative binomial specification.  We have experimented with a range of alternative procedures and approaches, including 
the conditional negative binomial estimator suggested by Hausman, Hall, and Griliches (1984) and the fixed effects 
estimator suggested by Allison and Waterman (2002).  Our core results are based on the traditional conditional fixed 
effects estimator with bootstrapped standard errors; however, our qualitative findings are consistent across these different 
procedures.  When using a conditional fixed effects estimator, one citation year and one age fixed effect are not 
separately identified (Hall, et al., 2007). 
  26
We further modify (1) to accommodate more flexible ways of identifying the impact of the 
policy intervention.  In particular, we estimate: 
(2) 
0 1 2
0 1 2
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where (2) decomposes the post-Bush policy period into effects associated with 2002-2003 and 2004-
2007 and (3) decomposes the pre- and post-policy periods into individual year*policy environment 
fixed effects.  The results of (2) will allow us to understand whether the post-policy effects are 
constant over time.  Estimating (3) enables us to estimate the year-by-year effects of the policy 
intervention and to check for the presence of a pre-policy time trend.  The former is important to 
understanding the dynamic consequences induced by the policy intervention – for example, whether 
the impact of the policy intervention occurs as a one-time change in the level of or diffusion of 
knowledge, whether it declines in relative terms or returns to baseline over time, or whether the 
policy intervention induces continuously growing effects.  The latter is important, as an 
understanding of the pre-policy time trend can provide evidence about the exogeneity of the policy 
intervention itself. 
In addition to examining the impact of the policy intervention on the extent of follow-on 
research in the U.S. and abroad, we are also interested in whether the policy shift affected the 
organization of hESC research.  In particular, we investigate whether the policy changes had a 
differential impact on elite and non-elite U.S. universities and on the geographic nature of research 
collaborations.  To estimate the impact of policy interventions on these subpopulations, we 
decompose annual citation counts by each subpopulation.  Specifically, in these analyses, we 
estimate a version of (2) in which we have three rather than two stacks of data.  When investigating 
the impact of the policy shift on elite and non-elite universities, the dependent variable in the first, 
second, and third stacks of the data reflect citations to root articles by (a) Top 25 U.S. universities, 
(b) Non Top 25 U.S. institutions, and (c) institutions outside the United States, respectively.18  We 
                                                 
18 We base our definition of elite universities on those classified as being in the “Top 25” by the Center for Measuring 
University Performance at Arizona State University’s 2006 Annual Report of University Research Rankings.  (Our 
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use this approach to investigate the impact of the policy shock on U.S.-international collaboration, by 
estimating a version of (2) in which the first, second, and third stacks of the data reflect citations to 
root articles by (a) authors from U.S. institutions only, (b) authors from both U.S. institutions Non-
U.S. institutions, and (c) authors from Non-U.S. institutions only, respectively. 
  
V. Empirical analysis  
V.1. Descriptive Statistics 
 Our complete dataset includes 719 root articles, of which 16 are human embryonic stem cell 
root articles, 51 are RNAi root articles, 559 are nearest neighbor articles and the remainder are 93 are 
other stem cell root articles.  We report descriptive statistics for the root articles in Table 1.  Panel A 
presents data for the entire sample of root articles; Panel B decomposes the data by article type 
(hESC, RNAi, nearest neighbor, and Other Stem Cells); and Panel C identifies the number of reprint 
authors by the country of origin for each of the reference groups.  Across the sample, more than 60 
percent of root articles include a reprint author based in the United States.  More than two-thirds of 
Reprint Authors’ addresses identify university affiliations; 24 percent of Reprint Authors are 
associated with “Top 25” universities, according to a classification scheme based on the Center for 
Measuring University Performance (Arizona State University) 2006 Annual Report of university 
research rankings.  Nearly half of the root articles involve papers with only U.S.-based authors; 13 
percent involve collaborations between U.S. and Non-U.S. authors; and 39 percent of root articles 
involve only authors based outside the United States.19  Panel C demonstrates that root articles are 
concentrated in the United States in each of the sample sub-groups.  The hESC root articles include 
reprint authors from Israel (4), Canada (2), and England (2) as well as the United States (5).  By 
contrast, the nearly three-quarters of the RNAi root articles include U.S.-based reprint authors.  If the 
number of pre-policy citations to these root articles were to reflect a similar fraction of U.S.-based 
authors, it would imply that the pre-policy intervention RNAi and hESC samples were poorly 
matched. 
 Table 2 reports bibliometric characteristics for annual citations received by our root article 
sample.  Panel A presents the data for the entire sample, while Panel B decomposes the data by 
                                                                                                                                                       
results are also robust to using the “Top 50” as defined by the same report.)  Articles are classified into these institutional 
categories based on the addresses of their reprint author.   
19 One issue worth noting in Panel B is that the fraction of U.S.-based authors is higher among RNAi root articles than 
hESC root articles.  If RNAi root articles received more citations from U.S.-based authors than did hESC root articles in 
the period after the initial discoveries enabling RNAi and hESC research (1998-2000), we may be worried that the initial 
geographic distribution of discovery drove the subsequent geographic distribution of follow-on research.  As the data we 
present below shows, however, the geographic distribution of RNAi and hESC research follows similar patterns between 
1998 and 2000. 
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article type.  On average, articles in our sample receive 17.3 citations per year, of which slightly less 
than half involve a US-based reprint author and only a small fraction of which involve collaboration 
between U.S. and Non-U.S. co-authors.  The standard deviation in Annual Citations is 39.4, which 
highlights the extent to which these data are skewed.  Similar to the root articles, the overwhelming 
majority of citations involve authors whose addresses can be linked to universities.  A smaller 
fraction of the citing articles, however, are associated with reprint authors affiliated with Top 25 
U.S.-universities.  There are some noteworthy differences across article types.  Whereas hESC root 
articles receive, on average, approximately 32 citations per year, RNAi root articles receive nearly 68 
citations.  In addition, RNAi articles receive more citations from U.S.-based authors.  The nearest 
neighbor sample is the least well-cited, receiving, on average, fewer than 9 citations annually.  This 
highlights the fact that the nearest neighbor articles are more representative of “normal science” than 
the RNAi or stem cells samples, each of which reflects a “hot” scientific field.  Panels C and D of 
Table 2 indicate the country of origin of citing article reprint authors for the periods before 2001 and 
after 2001, respectively.  The fraction of citations from U.S.-based authors in the pre-intervention 
period is similar in RNAi sample, which helps alleviate the worry that the initial geographic 
distribution of discovery drives the subsequent geographic distribution of follow-on research.  By 
contrast, the ratio of U.S. to Non-U.S. citing articles in the RNAi sample is higher in the post-
intervention period than it is in the hESC sample.  This fact about the raw data on citations is 
consistent with that found by Levine (2005, 2008).  In addition to the specific U.S. vs. Rest-of-the-
World comparisons, Panels C and D indicate the general research strength of Japan, Germany, and 
England in each area of science in our sample, as well as the relative strengths of Israel, China, and 
South Korea in hESC research and China in RNAi research.  Additional evidence regarding the 
strength of these countries in hESC and RNAi is found in Appendix Table 1, which documents the 
number of papers on which U.S. authors collaborate with authors from other countries.  The strength 
of specific research institutions is presented in Appendix Table 2, which lists the count of follow-on 
hESC by the Reprint Author’s institutions.  This table highlights the strength of Johns Hopkins, 
Wisconsin, Harvard, Stanford, and Geron in the United States and institutions outside the U.S., 
including Israel research organizations, such as Hebrew University, the Technion, and Rambam 
Medical Center, as well as Australia’s Monash University, the University of Sheffield, Kyoto 
University, and the National University of Singapore. 
  
V.2. Publication Trends 
 Figure 1 depicts the number of citing articles by broad article type and year, not 
distinguishing by country-of-origin.  There is an upward trend among each of the subsamples.  With 
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the exception of the hESC sample, the rate of follow-on publications accelerates noticeably between 
1998 and 2002 (or 2003, depending on the sub-sample).  The raw number of nearest neighbor 
citations is greatest.  This is not surprising, as the baseline number of nearest neighbor root articles is 
400 more than that of any other sub-sample.  Prior to 1999, the number of articles building on hESC 
and RNAi roots is relatively similar.  Beginning in 2000, however, the extent of cumulative research 
in these two areas diverges appreciably, as citations to the RNAi roots rise from fewer than 1,000 in 
2000 to more than 5,000 by 2004. 
 Figure 2 reports citing articles by publication type and year for U.S. and non-U.S. reprint 
authors.  It includes four separate graphics, one for each of our samples.  Each graphic reports the 
number of citations to a different root article sample by papers with either (a) any U.S.-based author 
or (b) no U.S.-based author.  In each case, the number of overall citations rises before falling in the 
final years of the sample.  The fact that the overall number of citations declines in the final few years 
of each graphic is reflective of a typical citation pattern, in which root articles receive the highest 
number of citations in the few years after their publication (Furman and Stern, 2011).  The rate of 
obsolescence is of less interest in our analysis than the relative levels of U.S.-based and non-U.S.-
based citations. 
 The top-most graphic in Figure 2 compares trends in citations to hESC root articles by U.S.-
based and non-U.S.-based reprint authors.  While the number of citations by each category is similar 
between 1998 and 2000, the counts diverge in 2001.  Specifically, while the growth rate of non-U.S.-
based citations continues after 2001 (until 2004), the relative number of US-based citations declines 
beginning in 2001, although there appears to be a modest recovery in 2004.  These findings are 
consistent with those reported by Owen-Smith and McCormick (2006), who conclude based on a 
keyword approach to identifying hESC publications up until 2004, that the U.S. share of hESC 
articles experienced a relative decline beginning in 2001.  The U.S. share of Other Stem Cell citing 
articles (i.e., articles citing “root” articles in areas of stem cell research other than hESC research) 
declines beginning in 2003, though not before.  U.S.-based citations to RNAi root articles and nearest 
neighbor root articles also experience a relative decline in the later years of the data, but do not 
experience a relative decline between 2001 and 2003. 
 Interpreting these trends requires care and more structured analysis.  In light of the relatively 
stable U.S. share of RNAi and nearest neighbor articles, the unambiguous relative decline of the U.S. 
share of hESC articles and modest relative decline in other stem cell articles may suggest that the 
shock to U.S. funding policy had an impact on the rate of follow-on stem cell research in the United 
States.  Consistent with the expectation that the 2000 election created substantial uncertainty about 
the future of hESC research in the United States, the relative decline in U.S. hESC share begins in 
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2001.  Consistent with the expectation that the U.S. policy did not enhance national hESC output, the 
relative decline appears to continue in the years after 2001 as well.  In order to identify the impact of 
the election and policy shock precisely, however, we employ the difference-in-differences techniques 
we describe above. 
 
V.3. Core Results 
Our descriptive statistics suggest the importance of measuring hESC research output relative 
to a carefully matched comparison group.  In addition, they highlight the importance of controlling 
for the impact of timing and root-article effects on follow-on research.  In our regression analyses we 
attend to these issues mainly by relying upon RNAi research as our control group.  Thus, we derived 
our counterfactual estimate of the impact of U.S. hESC policy by comparing geographic trends in 
hESC output to those experienced by RNAi research.  This seems to be an apt comparison, as both 
areas of research were pioneered in the United States in 1998; both by individuals at institutions of 
similar relative status, and both are in the same broad area of cell biology.  In our robustness checks, 
we compared the geographic evolution in hESC research to that of research using Other Stem Cells 
and science overall, based on a sample of nearest neighbor articles.  A principal concern with using 
Other Stem Cells as a control group is the possibility that hESC researchers could substitute into 
OSC research (and vice versa).  Techniques associated with research on human embryos could be 
applied to mouse embryos, for example.  The prospect of substitution between hESC research and 
RNAi research is unlikely (and citations are not overlapping), however, as the techniques and 
materials vary greatly.  The nearest neighbor articles also form a less satisfactory control group, as 
publications within a journal often vary in nuanced ways, even across subfields, thus, may have 
substantially different citation profiles. 
We present our regression results beginning in Table 3 with a conditional fixed effects 
negative binomial specification in which we estimate ritCITES  as the dependent variable with two 
“stacked” equations.  In the top stack, r USitCITES
  reflects citations by papers with reprint authors in 
the United States in the top stack of the data; in the bottom stack r Not USitCITES
   reflects citations by 
papers whose reprint authors are from countries other than the United States.  We do not report the 
significance of tests of joint restrictions on the article fixed effects, as these are not computed in 
conditional fixed effects models.  In addition to reporting raw coefficients and associated 
bootstrapped standard errors (MacKinnon, 2002), our tables report the coefficients in our results as 
incidence-rate ratios (IRRs), which are easily interpreted as percentage changes relative to a baseline 
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(i.e. the null hypothesis of no effect yields a coefficient of 1.00, while a coefficient equal to 1.50 
implies a 50% boost to FORWARD CITATIONS).   
Column (3-1) estimates the impact of U.S. policy on citations in year 2001 and in the average 
of the years following the shock (2001-2007).  Table 3 reports coefficients that reflect the relative 
output of hESC vs. RNAi research and U.S. vs. Non-U.S. hESC research.  Specifically, the 
coefficients on HESC*2001 and HESC*(2002-2007) indicate the boost in worldwide hESC output 
relative to RNAi output during the time periods 2001 and 2002-2007.  These are not statistically 
different from one.  The coefficients on US*HESC*2001 and US*HESC*(2002-2007) indicate the 
boost (or decrement) in U.S.-based hESC output during these periods relative to research output in 
countries other than the United States.  The magnitudes and significance levels of these coefficients 
imply that, relative to hESC research outside the United States, the production of follow-on research 
with any U.S. address declined severely beginning in 2001.  Indeed, in this specification, the impact 
of the shock is greatest in 2001, during which research output falls by slightly more than 51%.  In the 
years after the shock, the amount of hESC follow-on papers with a U.S.-based reprint author 
declines, on average, by 41%.  
By estimating the average treatment effect across the years 2002-2007, the specification in 
(3-1) masks some of the interesting dynamics associated with U.S.-based hESC research.  In (3-2), 
we decompose the post-policy time period into effects associated with the years 2002-2003 and 
2004-2007.  In the immediate years after the implementation of the Bush Administration policy, 
U.S.-based hESC follow-on work declines by nearly 59% relative to non-U.S. based research.  
However, during the period 2004-2007, the production of hESC follow-on papers is only 29% lower 
in the U.S. than the rest of the world.  We consider this dual finding – i.e. of initial relative decline in 
U.S. hESC research output followed by a research rebound – to be one of the core findings of our 
analysis.  Specifically, (3-2) suggests that the impact of the Bush Administration hESC was greatest 
in the first few years after its announcement and implementation, but that U.S. hESC output began to 
recover beginning in 2004, only a few years after the policy was enacted.  Although some state 
funding did begin to support hESC research in the U.S. during the 2004-2007 period, little of it had 
arrived by the time that the rebound had begun.   
We explore the year-to-year dynamics of the relative decline and partial rebound in U.S. 
hESC research output in the analysis in (3-3) and turn thereafter to an examination of some of the 
mechanisms of the recovery.  Specifically, in (3-3) we estimate a more flexible specification, in 
which we report year-by-year effects both for all hESC articles (relative to RNAi articles) and U.S.-
based hESC articles (relative to articles produced outside the U.S.).  Figure 3 plots the year-by-year 
hESC*U.S. incident rate ratio, along with the associated 95 percent confidence intervals.  The results 
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of this exercise underscore the findings reported in (3-2):  U.S.-based hESC output experiences a 
penalty relative to Non-U.S. hESC output in 2001, 2002, and 2003.  At its relative nadir in 2003, U.S. 
hESC output was only 40 percent of Non-U.S. output.  U.S. hESC output recovers between 2004 and 
2007, reaching levels that are approximately 66 to 74 percent of Non-U.S. output in 2004 and 2006, 
and to levels that are statistically indistinguishable from Non-U.S. output by 2007.  These results 
paint a picture that suggests that U.S. hESC research output experienced a substantial decline relative 
to its potential in the year in which the Bush Administration policy was enacted and the two that 
followed.  However, this decline is followed by what appears to be a steady rebound, which 
continues until the final year of our data, 2007. 
In Table 4, we show whether these results are an artifact of our particular sample and means 
of classifying national origin.  Column (4-1) replicates the analysis of (3-2), using an alternative 
measure of location in which citing articles are considered to be U.S.-based if any address in the list 
of author affiliations is based in the United States.  These results are qualitatively and quantitatively 
similar to those of (3-2).  Specifically, we find both an immediate relative decline in U.S.-based 
output in 2001, which continues in 2002 and 2003, along with a recovery between 2004 and 2007.   
Equation (4-2) reports the result of the same specification as (3-2), again using reprint author to 
identify the location of the paper; however, rather than comparing hESC output to the RNAi controls, 
the nearest neighbor articles are substituted for the controls.  The positive and significant coefficients 
on the HESC*YEAR variables suggest that hESC root articles received 59 percent, 92 percent, and 
160 percent more citations in 2001, 2002-2003, and 2004-2007 than did their nearest neighbor root 
articles, thus confirming that hESC research was a “hot” research area relative to normal science.  
The coefficients on US*HESC*YEAR compare the output of follow-on hESC articles in the U.S. to 
those outside the U.S., relative to geographic trends in citations to the nearest neighbor articles.  
These results are similar to those found using the RNAi control sample.  Once again, U.S. hESC 
output experiences a relative decline in 2001 and 2002-2003, but rebounds from 2004-2007.  The 
comparisons of U.S. to Non-U.S. output of hESC articles, RNAi articles, and nearest neighbor 
articles are consistent with a general phenomenon in which the global concentration of science is 
declining, as countries other than the United States increase their relative investments in scientific 
research.  The pattern is different, however, in (4-3), in which the control sample consists of Other 
Stem Cell root articles.  hESC research is neither especially “hot” nor especially “cold” in 
comparison to OSC research and the policy shift does not appear to affect one to a significantly 
greater degree than the other, with the exception that U.S.-hESC output declines in 2002 and 2003.  
Although we believe that the comparison of hESC and OSC output is illustrative, we do not believe 
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that OSC forms a suitable control sample for hESC research, as it is relatively easy for researchers to 
substitute from hESC research into OSC research (and vice versa).   
 
V.4. Mechanisms of Response and Sources of the Rebound 
Our analyses thus far have focused on identifying the extent of U.S.-based hESC research 
during various U.S. policy environments.  In Figures 4 and 5, we examine changes in the nature of 
U.S.-based hESC research, highlighting mechanisms that may partially explain the relative rebound 
in U.S. hESC output in the latter years of our sample.  Specifically, Figure 4 investigates the relative 
impact of the policy shift on elite U.S. universities relative to other institutions, while Figure 5 
investigates the impact of the policy shift on various types of research collaborations.  Figure 4 
compares the impact of the policy shock across three types of institutions:  (a) elite U.S. universities, 
(b) all other U.S. institutions, and (c) institutions outside the United States.  In these models, we have 
“triple-stacked” the data; coefficients on hESC*U.S.*Institution Type indicate the boost or decrement 
to the production of hESC papers by institutions of various types (Top-25 and Not-Top-25) in the 
U.S. in to the policy shift, each relative to citations from articles with Non-U.S. citing authors.   
The (unreported) average treatment effects imply a relative decline of approximately 33 
percent of output in the Top-25 U.S. universities and 46 percent among the non-elite universities.  
The year-by-year effects, however, imply that hESC output by the elite U.S. universities declined in 
2002 and 2003, but recovered nearly completely thereafter.  By contrast, hESC research output by 
U.S.-based reprint authors in other institutions experience a relative decline beginning in 2001, 
recovering somewhat, though not completely (either in magnitude or statistical significance) by the 
end of the study period.   
These results are consistent with interview-based evidence we have assembled, which 
suggests that the constraints applied by the Bush Administration policy were more likely to be 
binding for those institutions for which federal funding was a relatively more important source of 
funding, whereas those institutions that found it easy to obtain private funding were less negatively 
impacted by the policy.  Consider the Harvard Stem Cell Institute (HSCI) as an example of the type 
of research possible at elite institutions without federal funds.  Harvard University established the 
HSCI in 2004, incorporating researchers and practitioners from Harvard’s various colleges and 
affiliated hospitals.  In 2005, the HSCI had begun to disperse nearly $1.8 million in research grants 
(HSCI, 2005); by 2006, the HSCI had received approximately $50 million in donor support (HSCI, 
2006); and in 2009, the Institute dispersed $15.6 million in research funds, including some funds 
included in a five-year, $25 million targeted research grant from GlaxoSmithKline (HSCI, 2009).  
HSCI research on human embryonic stem cells is rigorously kept physically and organizationally 
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separate from research supported by federal funds (Dreifus, 2006) and several Harvard faculty 
maintain distinct laboratories for their hESC work.  It does appear to have taken a few years, 
however, for elite scholars and institutions, like Harvard, to attract substantial private research funds 
and to have generated the infrastructure necessary to ensure compliance with federal policies and 
begin to produce frontier research.  Moreover, the extent to which such substitution is possible may 
be limited both to a select set of institutions and to particular scientific fields, like hESC research, 
which are relatively small in comparison to other fields. 
We examined an additional mechanism by which U.S.-based hESC researchers may have 
responded to the policy shock in Figure 5.  Specifically, Figure 5 compares follow-on research across 
three collaboration-location types:  (a) papers with only U.S. authors, (b) papers with U.S. and Non-
U.S. authors (i.e., those with international collaboration), and (c) papers with no U.S. authors.  The 
results suggest that the output of papers with only U.S.-based authors declined more significantly 
than those of the other types following the policy shock.  The relative output of hESC papers 
involving collaboration between U.S. and non-U.S. authors declined significantly in the year of the 
policy shock (2001) but were unaffected by the policy shock thereafter.  This is a particularly 
interesting mechanism of response by the U.S. hESC community, which suggests that international 
scientific networks may help mitigate the impact of any one nation’s policies.  (The result is also 
consistent with the expectations of Garud and Rappa (1995) who propose that collaborations will 
play a role in shaping researcher commitment to a particular research area.) Taken together, these 
results are consistent with an explanation in which researchers (possibly those at more resource-
constrained institutions) in the U.S. collaborate with scientists outside the United States who may 
have less complex and better access to resources. 
 
VI. Discussion 
 This paper presents a detailed analysis of the impact of the 2001 U.S. Human Embryonic 
Stem Cell policy on the relative output of U.S. research building on seminal discoveries in hESC 
research.  Our results suggest that U.S. hESC research output experienced a statistically significant 
and quantitatively meaningful decline relative to hESC research output in the rest of the world, when 
comparing to the trend anticipated by the relative U.S. share of RNAi research output.  The relative 
decline in U.S. hESC output is most severe in 2001, the year in which the uncertainty about U.S. 
federal funding policy was resolved. 
  
 The extent to which the observed patterns of US activity in stem cell research output are a 
direct consequence of the targeted funding policy per se or whether other unobservable factors 
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affected U.S. hESC research beginning in 2001 is open to interpretation.  It is possible that 
uncertainty surrounding the 2001 policy, rather than the policy itself, may have discouraged research 
efforts during the early 2000s.  The data make clear that the hESC policy environment (i.e., both the 
uncertainty and the policy), strongly influenced U.S. hESC research output relative to what would 
have been expected given the experience of RNAi.  While our results are consistent with the 
observation that scientific and technical capabilities are increasingly globalized (Furman and Hayes, 
2004), our analysis suggests that U.S. policies can accelerate the globalization of science if they 
employ funding targets that are inconsistent with the preferences of research scientists or place 
constraints on research autonomy within the United States.   
 Considering the limited support for U.S. hESC research and the much more explicitly 
supportive policy environments of a number of other countries, including South Korea, Singapore, 
and Israel, perhaps the biggest surprise in our results is the long-term robustness of the United States 
hESC research community to system perturbations.  We thus interpret our overall findings as 
consistent with a picture in which the national-level institutions that support scientific 
competitiveness and scientific autonomy are robust and relatively enduring.  Overall, once scientists’ 
willingness to find alternative mechanisms to pursue their chosen paths is taken into account, the 
impact of the Bush Administration targeting may be of second-order importance relative to issues 
such as the extent of overall funding.20 
 By considering how the research trajectories of the U.S. scientific community responded to 
the complex policy context for hESC research in the 2001 (and earlier) period, our paper provides the 
first causal assessment of this highly controversial public policy (reversed in 2009 by order of the 
Obama Administration, subject to continued legal deliberation).  Our evaluation of this changing 
policy environment addresses and clarifies a series of debates among policy-makers, including those 
who consider science policy in the context of national competitiveness (Marburger, 2005; Jaffe, 
2006).  Specifically, it provides insight into the degree to which national funding agencies (as well as 
those operating at the state level or in the private sector) can shape overall participation in a particular 
research trajectory, alter the composition of researchers in a particular research area, or affect the 
nature of collaboration in a field.  Our results suggest that scientists exhibit considerable agency with 
regards to maintaining their research direction, thus implicitly raising questions as to the relative 
power of funders to shape the national research portfolio (Gans and Murray 2011).   
 A further contribution of our paper is to exemplify recent developments in science policy 
evaluation, often referred to as the “Science of Science Innovation Policy.”  By developing this paper 
                                                 
20 We are grateful to Paula Stephan for pointing this out in careful Discussant commentary on this paper. 
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as both an empirical exercise in its own right and a primer on the citation-based approach to policy 
evaluation, we hope to have an impact on a range of scholars in the science policy community.  Our 
analysis illustrates the benefits of the citation-based approach, while highlighting the difficulties 
associated with science policy evaluation, even using these advanced econometric techniques.  At the 
core of the challenges is the ability to define a clear policy intervention, assess its likely impact on 
the scientific community, find appropriate measures of scientific activities in the pre- and post- 
period, and define a clear counterfactual.  The citation-based approach provides a clear framework 
within which to undertake such as analysis.  However, it is also limited in that is focuses specifically 
on having a precise understanding of the nature of the policy intervention and on examining the 
impact of the intervention on research trajectories.  As we have shown in our earlier work (e.g., 
Murray and Stern, 2007; Furman and Stern, 2011; Furman, Jensen, and Murray, 2012), this approach 
is most powerfully applied to institutional and policy changes that are tightly coupled to specific 
research paths and research areas.  Broadening to the more complex hESC policy is at once an 
opportunity and a challenge.  The messy hESC situation imposes limits on the precision with which 
we can interpret the results of our analysis.  Nonetheless, the approach provides complementary 
insights to the work of others in the hESC area who have focused on tracing out the activities of 
specific scientists, particular research areas or key research materials. 
 Lastly, and most broadly, our analysis of the stem cell policy environment illuminates some 
critical issues in the microeconomic and institutional foundations of scientific progress (Mokyr, 
2002).  Although “Open Science” is widely recognized to play a fundamental role in the production 
of fundamental knowledge (Merton, 1973; Dasgupta and David, 1994; David 1998, 2001, 2008; 
Stephan, 1996), few formal analyses support our understanding of the impact of specific and often 
subtle policies and practices on scientific progress.  Beyond simple determination of the level of 
participation, our analysis suggests that policies may have important, though unintended, 
distributional consequences:  For example, policies may have an impact on national scientific 
advantage by changing the degree to which researchers engage in a particular trajectory relative to 
the rest of the world.  Our findings also remind us that scientific progress takes place in an 
increasingly globalized context, with scientists (particularly at elite universities) strategically acting 
to select international scientific collaborators from where policies may be less restrictive.  This 
underscores the unintended consequences of implementing national policies in the context of the 
global scientific community. 
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Table 1 – Descriptive Statistics – Root Articles 
 
Panel A:  Characteristics of Articles, entire sample* 
Variable (n=719) Mean Std. Dev. Min Max 
Publication Year 1997.45 3.94 1976 2002 
Reprint Author based in US 0.61 0.49 0 1 
Reprint Author based in University 0.68 0.47 0 1 
Reprint Author at Top 25 US University 0.24 0.43 0 1 
Paper with Only US author(s) 0.47 0.50 0 1 
Paper with Any US author(s) 0.59 0.49 0 1 
Paper with both US & Non-US authors 0.13     0.34 0 1 
Paper with No US authors 0.39 0.49 0 1 
 
 
Panel B:  Characteristics of Articles, by article type* 
 
hESC  
(n=16) 
RNAi  
(n=51) 
Nearest Neighbors 
(n=559) 
Other Stem Cells 
(n=93) 
Variable Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. Mean Std. Dev.
Publication Year 1995.19 6.01 1999.84 2.61 1997.36 3.81 1997.11 4.41 
Reprint Author based in US 0.33 0.49 0.76 0.43 0.61 0.49 0.56 0.50 
Reprint Author based in Uni 0.87 0.35 0.56 0.50 0.68 0.47 0.69 0.47 
Reprint Author at Top 25 US Uni 0.27 0.46 0.20 0.40 0.25 0.43 0.19 0.39 
Paper with Only US author(s) 0.19 0.40 0.59 0.50 0.47 0.50 0.43 0.50 
Paper with Any US author(s) 0.31 0.48 0.71 0.46 0.59 0.49 0.52 0.50 
Paper with both US & Non-US authors 0.14 0.36 0.13 0.34 0.14 0.35 0.09 0.29 
Paper with No US authors 0.67 0.49 0.24 0.43 0.39 0.49 0.44 0.50 
Reprint Author blank 0.06 0.25 0.12 0.33 0.20 0.40 0.25 0.43 
Address/Institution field blank 0.13 0.34 0.08 0.27 0.09 0.29 0.05 0.23 
* The percentage of US + Non-US authors does not sum to 1, as Reprint Author data are blank (not specified or not recorded) for 142 of 
the 719 root articles. 
 
 
Panel C:   Counts of Reprint Author by Country of Origin (for top nine countries of origin)^ 
hESC RNAi NN* OSC* 
RP Country # papers RP Country # papers RP Country # papers RP Country # papers 
USA 5 USA 34 USA 271 USA 39 
Israel 4 Germany 4 England 27 Japan 5 
Canada 2 Netherlands 3 Germany 26 England 4 
England 2 Italy 1 Australia 16 Germany 7 
  Japan 1 France 15 Australia 2 
  Norway 1 Japan 11 Austria 2 
    Italy 10 Canada 2 
    Canada 9 France 2 
    France 8 Italy 2 
^ Note that Reprint Author addresses are not available for all papers. 
* Table omits countries with fewer than two RP authors on OSC papers and fewer than eight RP authors on NN root articles. 
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Table 2 – Descriptive Statistics – Characteristics of Annual Citations Received by Root Articles 
 
Panel A:  Characteristics of Annual Citations Received (citation-year observations), entire sample* 
Variable Mean Std. Dev. Min Max 
Citing Year 2002.54 3.06 1996 2007 
Annual Citations 17.26 39.36 0 698 
Annual citations received from articles with… 
Reprint Author based in US 7.33 16.66 0 305 
Reprint Author based outside US 9.93 23.65 0 516 
Reprint Author based at University 11.12 25.65 0 487 
Reprint Author based at Top 25 US University 2.39 5.55 0 95 
Paper include Any US author(s) 8.30 18.46 0 344 
Paper include Only US author(s) 6.50 14.71 0 270 
Paper with both US & Non-US authors 1.81 4.13 0 74 
Paper with no US authors 8.95 21.74 0 477 
Papers in which RP author missing 0.24 0.43 0 1 
Papers in which Address data (C1) missing 0.11 0.31 0 1 
 
 
Panel B:  Characteristics of Annual Citations Received, by article type* 
 
hESC 
(n=159) 
RNAi 
(n=403) 
Nearest Neighbors 
(n=5382) 
Other Stem Cells 
(n=901) 
Variable Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. Mean Std. Dev.
Citing Year 2002.32 3.19 2003.33 2.68 2002.50 3.07 2002.47 3.09 
Annual Citations 32.03 55.05 67.95 94.61 8.69 16.01 43.18 58.45 
Annual Citations received from articles with…         
Reprint Author based in US 11.06 19.43 31.53 41.80 3.84 7.44 16.70 22.50 
Reprint Author based outside US 20.97 36.19 36.42 54.31 4.85 9.35 26.48 37.66 
Reprint Author based at University 20.26 35.15 41.39 59.42 5.74 11.01 28.09 39.96 
Reprint Author based at Top 25 US University 4.14 7.66 10.18 13.64 1.27 2.75 5.25 7.22 
Paper include Any US author(s) 12.83 22.02 34.49 46.24 4.40 8.26 19.13 24.99 
Paper include Only US author(s) 9.60 16.77 28.12 36.63 3.36 6.53 15.00 19.98 
Paper with both US & Non-US authors 3.23 5.79 6.37 10.16 1.04 2.11 4.13 5.70 
Paper with no US authors 19.19 33.44 33.47 49.67 4.29 8.48 24.05 34.95 
Papers in which RP author missing 0.08 0.26 0.16 0.37 0.24 0.43 0.30 0.46 
Papers in which Address data (C1) missing 0.15 0.36 0.10 0.31 0.11 0.31 0.06 0.24 
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Table 2 (continued) – Descriptive Statistics – Characteristics of Citing Articles 
 
Panel C:  Citing Articles by RP Author country of origin (citing articles published in or before 2001) 
hESC RNAi NN OSC 
RP Country # papers RP Country # papers RP Country # papers RP Country # papers 
USA 442 USA 1,383 USA 7,266 USA 3,883 
England 122 England 258 England 1,058 Germany 686 
Germany 64 Germany 166 Germany 1,041 Japan 567 
Australia 61 France 152 Japan 1,012 England 531 
Japan 45 Japan 126 France 760 France 482 
Israel 43 Netherlands 90 Canada 506 Canada 427 
France 38 Austria 65 Italy 382 Italy 334 
Canada 36 Australia 59 Switzerland 319 Australia 215 
Netherlands 35 Italy 58 Netherlands 278 Sweden 132 
 
Panel D:  Citing Articles, RP Author country of origin (citing articles published in or after 2002)  
hESC RNAi NN OSC 
RP Country # papers RP Country # papers RP Country # papers RP Country # papers 
USA 1,604 USA 12,708 USA 16,083 USA 13,387 
England 461 Japan 2,314 Japan 2,812 Japan 4,208 
Israel 348 Germany 2,119 Germany 2,758 Germany 2,996 
Japan 330 China 1,793 England 2,384 England 2,242 
Germany 267 England 1,243 France 1,469 China 1,829 
China 181 France 843 Canada 1,331 Italy 1,635 
South Korea 173 Netherlands 665 Italy 1,251 France 1,319 
Australia 168 Canada 605 China 983 Canada 1,206 
Canada 155 Italy 538 Netherlands 806 South Korea 861 
Singapore 117 South Korea 461 Spain 663 Australia 675 
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Table 3:  Core Results – US hESC Output vs. Rest-of-World (1996-2007) 
 
 CONDITIONAL FIXED EFFECTS NEG BINOMIAL, STACKED 
[Incidence-Rate Ratios in brackets in top line] 
Estimated coefficients in 2nd line 
(Block bootstrapped SEs reported in parentheses) 
DV = Cites with U.S. Reprint Author (or Not U.S. Reprint Author) 
 (3-1) (3-2) (3-3) 
HESC*2001 [1.081] 
0.078 
(0.203) 
[1.190] 
0.174 
(0.298) 
 
HESC*(2002-2007) [1.079] 
0.076 
(0.336) 
  
HESC*(2002-2003)  [1.073] 
0.070 
(0.323) 
 
HESC*(2004-2007)  [1.284] 
0.250 
(0.346) 
 
US*HESC*2001 [0.488] 
-0.718 
(0.210)*** 
[0.489] 
-0.715 
(0.227)*** 
 
US*HESC*(2002-2007) [0.589] 
-0.530 
(0.108)*** 
  
US*HESC*(2002-2003)  [0.413] 
-0.883 
(0.134)*** 
 
US*HESC*(2004-2007)  [0.711] 
-0.341 
(0.111)*** 
 
HESC*1996   [1.332] 
0.287 
(0.831) 
HESC*1997   [1.534] 
0.428 
(0.921) 
HESC*1998   [1.507] 
0.410 
(0.891) 
HESC*1999   [1.591] 
0.464 
(0.824) 
HESC*2000   [0.905] 
-0.099 
(0.765) 
HESC*2001   [1.343] 
0.295 
(0.715) 
HESC*2002   [1.144] 
0.134 
(0.747) 
HESC*2003   [1.275] 
0.243 
(0.821) 
HESC*2004   [1.287] 
0.252 
(0.815) 
HESC*2005   [1.480] 
0.392 
(0.827) 
HESC*2006   [1.653] 
0.503 
(0.842) 
HESC*2007   [1.474] 
0.388 
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(0.885) 
US*HESC*1996   [1.197] 
0.180 
(0.687) 
US*HESC*1997   [1.057] 
0.055 
(3.016) 
US*HESC*1998   [0.855] 
-0.157 
(0.636) 
US*HESC*1999   [0.635] 
-0.454 
(0.259)* 
US*HESC*2000   [0.891] 
-0.116 
(0.217) 
US*HESC*2001   [0.491] 
-0.712 
(0.244)*** 
US*HESC*2002   [0.425] 
-0.856 
(0.218)*** 
US*HESC*2003   [0.402] 
-0.912 
(0.145)*** 
US*HESC*2004   [0.667] 
-0.405 
(0.158)** 
US*HESC*2005   [0.737] 
-0.305 
(0.116)*** 
US*HESC*2006   [0.659] 
-0.418 
(0.159)*** 
US*HESC*2007   [0.793] 
-0.231 
(0.211) 
Article*Year Observations 1124 1124 1124 
Number of articles 67 67 67 
Log Likelihood -3187.15 -3169.81 -3161.86 
Models include unreported constant, hESC*YearFEs, Stack-specific Year FEs, Stack FEs, Article Age FEs, and Article FEs 
Bootstrapped standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1% 
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Table 4:  Exploring robustness of core results to an alternative measure of location and to 
alternative control samples 
 
 CONDITIONAL FIXED EFFECTS NEG BINOMIAL, STACKED 
[Incidence-Rate Ratios in brackets in top line] 
Estimated coefficients in 2nd line 
(Block bootstrapped SEs reported in parentheses) 
 (4-1) 
Sample:  hESC & RNAi 
articles 
DV = Cites with any US 
author (or No US author)
(4-2) 
Sample:  hESC & nearest 
neighbor articles 
DV = Cites with US 
Reprint Author (or Not US 
Reprint Author) 
(4-3) 
Sample:  hESC & OSC 
articles 
DV = Cites with US 
Reprint Author (or Not US 
Reprint Author) 
HESC*2001 [1.250] 
0.224 
(0.212) 
[1.594] 
0.466 
(0.115)***
[0.999] 
-0.001 
(0.205) 
HESC*(2002-2003) [1.078] 
0.076 
(0.292) 
[1.918] 
0.651 
(0.163)***
[0.853] 
-0.159 
(0.239) 
HESC*(2004-2007) [1.333] 
0.287 
(0.351) 
[2.579] 
0.947 
(0.213)***
[0.898] 
-0.107 
(0.272) 
US*HESC*2001 [0.492] 
-0.709 
(0.155)***
[0.627] 
-0.467 
(0.210)**
[0.716] 
-0.335 
(0.232) 
US*HESC*(2002-2003) [0.477] 
-0.741 
(0.144)***
[0.540] 
-0.616 
(0.142)***
[0.641] 
-0.445 
(0.139)***
US*HESC*(2004-2007) [0.731] 
-0.314 
(0.069)***
[0.775] 
-0.255 
(0.105)**
[1.050] 
0.049 
(0.107) 
Article*Year Observations 1124 10964 2102 
Number of articles 67 569 108 
Log Likelihood -3187.15 -17938.24 -5644.91 
Models include unreported constant, hESC*YearFEs, Stack-specific Year FEs, Stack FEs, Article Age FEs, and Article FEs 
Bootstrapped standard errors in parentheses 
* significant at 10%; ** significant at 5%; *** significant at 1% 
 
 
 
 
  48
Figure 1 – Citing articles by year 
 
 
 
 
  
Figure 2 – Citing articles by publication type and year, U.S. vs. Non-U.S. Reprint Auth
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Figure 3 – U.S. hESC Output vs. Rest-of-World (1996-2007) 
Figure 3 graphs the year-by-year incident rate ratios on hESC*US obtained in (3-3), including the upper and lower 
bounds on the 95% confidence intervals implied by the bootstrapped standard errors. 
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Figure 4 –hESC research output by Elite U.S. Universities & All Other U.S. Institutions 
Figure 4 reports the results of conditional fixed negative binomial regressions with a structure similar to (3-3), which 
contains three stacks of the data, reflecting citations by papers with (a) Reprint Authors based at the Top 25 U.S. 
universities, (b) all other U.S. institutions, and (c) institutions outside the United States.  Specifically, the figure 
reports incident rate ratios for year-specific variables reflecting hESC*(U.S. TOP 25 UNIVERSITIES) and 
hESC*(ALL OTHER U.S. INSTITUTIONS).  The figure also reports confidence intervals based on bootstrapped 
standard errors.  The regressions also include unreported constant, hESC*YearFEs, Stack-specific Year FEs, Stack 
FEs, Article Age FEs, and Article FEs. 
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Figure 5 –Collaboration between U.S. & Non-U.S. authors  
Figure 5 reports the results of conditional fixed negative binomial regressions of the type reported in (3-3), which 
contains three stacks of the data, which reflect citations by papers with papers with only U.S. authors, (b) papers 
with U.S. and Non-U.S. authors, and (c) papers with no U.S. authors. Specifically, the figure reports incident rate 
ratios for year-specific variables reflecting hESC*(US ONLY AUTHORS) and hESC*(US&NON_US 
COLLABORATION).  The regressions also include unreported constant, hESC*YearFEs, Stack-specific Year FEs, 
Stack FEs, Article Age FEs, and Article FEs. 
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Appendix Table 1: 
Citing Papers involving Collaborations between U.S. and other country, by sample and time period 
 
hESC 
2001 and 
prior 
Post-
2001 RNAi 
2001 and 
prior 
Post-
2001 
Germany 20 62 France 45 196 
England 18 59 Germany 32 309 
Japan 12 45 England 31 195 
Canada 11 49 Canada 29 192 
Italy 9 32 Netherlands 29 110 
France 9 20 Switzerland 29 113 
Israel 9 37 Japan 28 307 
Sweden 8 20 Australia 15 66 
Netherlands 7 24 South Korea 13 78 
Switzerland 3 6 Singapore 8 35 
Australia 3 33 Sweden 6 67 
Belgium 2 4 Israel 4 81 
Denmark 2 1 Taiwan 4 32 
Poland 1 5 Italy 3 115 
Czech 1 4 China 3 274 
China 0 23 Czech 3 19 
South Korea 0 30 Poland 2 18 
Singapore 0 21 Spain 2 61 
Spain 0 7 Denmark 2 28 
Taiwan 0 11 Belgium 0 29 
 
* Collaboration defined as paper that includes at least one U.S.-based address and at least one country other than the 
U.S. in the address field.  Note that same paper may involve collaborations with multiple other countries.  
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Appendix Table 2 – Panel A: 
hESC Citing Papers, Ranked by papers per Institutions with U.S.-based Reprint Authors 
 
Institution 
2001 & 
Prior Institution Post-2001
U WISCONSIN* 26 JOHNS HOPKINS U* 98 
WISTAR INST ANAT & BIOL 18 U WISCONSIN* 76 
U MICHIGAN* 19 HARVARD U* 59 
U PENNSYLVANIA* 17 STANFORD U* 51 
NINDS 14 GERON CORP 47 
JOHNS HOPKINS U* 11 NIA 43 
THOMAS JEFFERSON U 11 U MINNESOTA* 41 
HARVARD U* 9 MIT* 40 
MEM SLOAN KETTERING CANC CTR 9 UC SAN DIEGO 32 
U WASHINGTON* 9 WAKE FOREST U 32 
WASHINGTON U* 9 UC SAN FRANCISCO* 28 
NCI 8 U FLORIDA 24 
U MINNESOTA* 8 U TEXAS 23 
GERON CORP 7 U SOUTHERN CALIFORNIA 22 
MICHIGAN STATE U 7 U PITTSBURGH 21 
NINCDS 7 CHILDRENS HOSP 20 
U FLORIDA 7 COLUMBIA U* 18 
BAYLOR COLL MED 6 U GEORGIA 18 
OREGON HLTH SCI U 6 U WASHINGTON* 18 
ADV CELL TECHNOL 5 BAYLOR COLL MED 16 
MASSACHUSETTS GEN HOSP 5 U PENNSYLVANIA* 16 
OREGON REG PRIMATE RES CTR 5 WHITEHEAD INST BIOMED RES 16 
U ILLINOIS 5 UC LOS ANGELES 15 
U SOUTH FLORIDA 5 WASHINGTON U* 15 
 * Indicates institution classified as Top 25 U.S. research university. 
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Appendix Table 2 – Panel B: 
hESC Citing Papers, Ranked by papers per Institutions with Non-U.S.-based Reprint Authors 
 
Institution 2001 & Prior Institution 
Post-
2001 
MONASH UNIV 42 HEBREW UNIV JERUSALEM 108 
UNIV CAMBRIDGE 23 TECHNION ISRAEL INST TECHNOL 94 
NETHERLANDS INST DEV BIOL 18 MONASH UNIV 83 
UNIV SHEFFIELD 18 UNIV SHEFFIELD 73 
HEBREW UNIV JERUSALEM 16 RAMBAM MED CTR 71 
UNIV EDINBURGH 11 KYOTO UNIV 53 
UNIV OXFORD 11 NATL UNIV SINGAPORE 51 
TECHNION ISRAEL INST TECH 10 SEOUL NATL UNIV 45 
UNIV MIGUEL HERNANDEZ 10 UNIV CAMBRIDGE 41 
CNR 9 UNIV LONDON IMPERIAL COLL 41 
OSAKA UNIV 9 UNIV TORONTO 41 
UNIV BONN 9 UNIV EDINBURGH 34 
WELLCOME CRC INST 8 JOHN P ROBARTS RES INST 33 
HADASSAH UNIV HOSP 7 UNIV DURHAM 31 
INST PLANT GENET & CROP PLANT RES 7 UNIV NOTTINGHAM 30 
UNIV TORONTO 7 CELLARTIS AB 27 
CHIBA UNIV 6 NETHERLANDS INST DEV BIOL 27 
INST PASTEUR 6 ROSLIN INST 27 
KYOTO UNIV 6 LUND UNIV 26 
MT SINAI HOSP 6 MIZMEDI HOSP 25 
UNIV LIVERPOOL 6 SHINSHU UNIV 21 
INST CHILD HLTH 5 UNIV COLOGNE 21 
IPK GATERSLEBEN 5 OSAKA UNIV 20 
MAX PLANCK INST IMMUNBIOL 5 ROYAN INST 20 
MED UNIV LUBECK 5 SHANGHAI JIAO TONG UNIV 20 
PPL THERAPEUT 5 TEL AVIV UNIV 20 
UNIV COLOGNE 5 UNIV BONN 20 
 
